

BMJ Open

Health service utilization for anogenital warts in Ontario prior to the human papillomavirus (HPV) vaccine program introduction

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2015-009914
Article Type:	Research
Date Submitted by the Author:	04-Sep-2015
Complete List of Authors:	Guerra, Fiona; Public Health Ontario, Applied Immunization Research Rosella, Laura; University of Toronto, Dalla Lana School of Public Health; Public Health Ontario, Public Health Sciences Dunn, Sheila; University of Toronto, Family and Community Medicine; Women's College Hospital, Family and Community Medicine Wilson, Sarah; Public Health Ontario, Immunization and vaccine-preventable diseases; University of Toronto, Dalla Lana School of Public Health Chen, Cynthia; Public Health Ontario, Knowledge Services Deeks, Shelley; Public Health Ontario, Immunization and vaccine-preventable diseases; University of Toronto, Dalla Lana School of Public Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Sexual health, Public health
Keywords:	EPIDEMIOLOGY, GENITOURINARY MEDICINE, Community gynaecology < GYNAECOLOGY, Epidemiology < INFECTIOUS DISEASES, SEXUAL MEDICINE

SCHOLARONE™
Manuscripts

1
2
3 Health service utilization for anogenital warts in Ontario prior to the human
4
5 papillomavirus (HPV) vaccine program introduction
6
7

8
9 Fiona M. Guerra¹, Laura C. Rosella^{1,2,3}, Sheila Dunn^{4,5}, Sarah E. Wilson^{1, 2,3}, Cynthia
10
11 Chen¹, Shelley L. Deeks^{1,2}
12

13
14 ¹Public Health Ontario, Toronto, ON, CA
15

16
17 ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, CA
18

19
20 ³Institute for Clinical Evaluative Sciences, Toronto, ON, CA
21

22
23 ⁴Department of Family and Community Medicine, University of Toronto, ON, CA
24

25
26 ⁵Women's College Hospital and Women's College Research Institute, Toronto, ON, CA
27
28

29
30 Corresponding author: Fiona M. Guerra, MPH, PhD
31

32
33 Postdoctoral fellow, Applied Immunization Research
34

35
36 Public Health Ontario
37

38
39 480 University Ave., Suite 300, Toronto, ON, M5G 1V2
40

41
42 Phone: (647) 260-7591
43

44
45 Fax: (647) 260-7600
46

47
48 fiona.guerra@gmail.com
49

50
51
52 Key Words: genital warts; anogenital warts; human papillomavirus; epidemiology of
53
54 genital warts
55
56
57
58
59
60

Word Count: 3023

ABSTRACT

Background: Trends in occurrence of anogenital warts (AGWs) can provide early evidence of human papillomavirus (HPV) vaccination program impact on preventing HPV infection. Therefore, baseline AGW epidemiology prior to the introduction of Ontario's HPV vaccination program is required to evaluate program impact.

Objective: To provide a baseline of AGW epidemiology in Ontario prior to the introduction of the publicly-funded school-based HPV vaccination program in fall 2007.

Methods: As a retrospective longitudinal population-based study, we used health administrative data to identify incident AGWs and total health service utilization (HSU) for AGWs for all Ontario residents 15 years and older with valid health cards between April 1 2003 and March 31 2007. An AGW case was considered incident if preceded by 12 months without HSU for AGWs. Time trends by age group and sex were analyzed.

Results: Between fiscal years 2003 and 2006, we identified 123 247 health service visits for AGWs by 51 436 Ontario residents 15 years and older. Incident AGWs peaked in females in the 21-23 year age group, at 3.74 per 1000, and peaked in males in the 24-26 year age group at 2.81 per 1000. HSU for AGWs peaked in both females and males within the 21-23 age group, at 9.34 per 1000 and 7.22 per 1000, respectively.

1
2
3 **Conclusion:** To our knowledge, this is the first population-based study of HSU for
4
5 AGWs in Ontario. The sex and age distribution of AGWs in Ontario was similar to that
6
7 of other provinces before HPV vaccine program implementation in Canada.
8
9

10 11 STRENGTHS AND LIMITATIONS OF THE STUDY 12

- 13
14 • AGWs are an early indicator of HPV transmission. We report the baseline of AGW
15
16 epidemiology in Ontario-Canada's most populous and ethnically diverse province-
17
18 in the years leading up to the introduction of the publicly-funded, female-targeted
19
20 school-based HPV vaccination program.
21
22
- 23
24 • We used health administrative data to identify incident AGWs and health service
25
26 utilization (HSU) for AGWs for Ontario residents 15 years and older. These
27
28 databases are consistent with administrative data used to estimate AGW burden in
29
30 previous studies.
31
32
- 33
34 • The databases used do not capture AGW-related health visits to providers not
35
36 captured by fee-for-service remuneration models without shadow billing, including
37
38 sexual health clinics, public health clinics, and community health centres, nor does
39
40 the data capture undiagnosed and untreated AGWs. Thus, the data are an
41
42 underestimate of the true incidence of AGWs.
43
44
- 45
46 • The data may be impacted by changes to clinical practices in terms of
47
48 compensation, coding, treatment etc., which were not accounted for here.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Most individuals will acquire human papillomavirus (HPV) at some point in their
4
5 lifetime. HPV can be transmitted by vaginal, anal, and oral sex, as well as non-
6
7 penetrative sex including digital-vaginal or skin-to-skin contact (1), and through
8
9 vertical transmission (2). Although most HPV infections are transient and resolve
10
11 without treatment, HPV infection can lead to both benign and cancerous conditions.
12
13 At least 150 different HPV genotypes have been described, with approximately 40
14
15 genotypes having tissue specificity for the anogenital region and oral cavity (3). HPV-6
16
17 and -11 accounted for approximately 90% of anogenital warts (AGWs), while HPV-16
18
19 and -18 accounted for approximately 70% of cervical cancers prior to vaccine
20
21 introduction (4). HPV is also associated with other anogenital cancers (vaginal, vulvar,
22
23 penile, anal canal) and a subset of head and neck squamous cell carcinomas. The
24
25 licensing of prophylactic HPV vaccines Gardasil® (referred to as HPV4 vaccine,
26
27 targeting HPV types 6, 11, 16, and 18, by Merck & Co., Whitehouse Station, NJ USA)
28
29 and Cervarix® (targeting HPV types 16 and 18, by GlaxoSmithKline Biologicals,
30
31 Rixensart, Belgium) in countries around the world starting in 2006 introduced the
32
33 possibility of primary prevention for HPV-related malignancy with both vaccines, and
34
35 AGWs with HPV4 vaccine.
36
37
38
39
40
41
42
43
44

45 Also known as condylomata accuminata, AGWs appear as multiple, asymmetric
46
47 epithelial growths on the anogenital skin or mucous membranes. They can fluctuate
48
49 in size and number, and can be flat, papular, cauliflower-like or keratotic. Anogenital
50
51 warts are associated with significant costs to the health care system (5) and can cause
52
53 substantial psychological distress (6), as well as pain and discomfort in some cases in
54
55 the form of itching, discharge, burning, or bleeding (7, 8). Approximately 70% of HPV-
56
57
58
59
60

1
2
3 6/11 infections are cleared within 12 months (9, 10), with 10-30% of AGW cases
4
5 clearing spontaneously within three months (11). Treatments used in Canada include
6
7 topical therapies applied by a physician or the patient, or physician administered
8
9 ablative treatments such as cryotherapy, electrosurgery, CO2 laser, or surgical
10
11 excision (12).
12
13

14
15
16 Trends in health service utilization (HSU) for AGWs can provide an early indication of
17
18 the impact of Ontario's HPV vaccine program in preventing HPV infection, by providing
19
20 valuable information on the burden of AGWs pre- and post-vaccine program
21
22 implementation. Other countries with HPV vaccination programs have begun reporting
23
24 significant decreases in the incidence of AGWs in females targeted for vaccination
25
26 since the introduction of their programs (reviewed by 13, 14). Several Canadian
27
28 provinces have conducted baseline studies of AGW epidemiology in anticipation of
29
30 evaluating HPV vaccine program impact, reporting peak incidence rates for males and
31
32 females ranging from 3.03 to 3.92/1000 population and 3.38 to 4.66/1000 population,
33
34 respectively (5, 15, 16).
35
36
37
38
39

40
41 The objective of our report is to provide a baseline of AGW epidemiology in Ontario in
42
43 the years leading up to the introduction of the publicly-funded, female-targeted
44
45 school-based HPV vaccination program, which was introduced in the fall of 2007.
46
47

48 **METHODS**

49 **Databases**

50
51
52
53
54
55 Neither AGWs nor HPV infection are reportable diseases in Ontario, therefore there
56
57 are no surveillance data to derive incidence and prevalence. Data are available on
58
59
60

1
2
3 AGW-related HSU in Ontario through a variety of health administrative databases held
4
5 at the Institute for Clinical and Evaluative Sciences. The Ontario Health Insurance Plan
6
7 (OHIP) database captures fee-for-service claims made by Ontario physicians, and
8
9 represents claims from approximately 98% of physicians in the province (17). The OHIP
10
11 database was used to identify physician visits for AGWs using a combination of
12
13 diagnostic and procedural codes. The Canadian Institute of Health Information (CIHI)-
14
15 Discharge Abstract Database (DAD) was used to identify hospitalizations for AGWs. The
16
17 CIHI National Ambulatory Care Reporting System (NACRS) covers hospital and
18
19 community-based ambulatory care services, and was used to identify emergency
20
21 department (ED) visits for AGWs. The Same-Day-Surgery (SDS) database was used to
22
23 identify same day surgeries and procedures for AGWs. The Registered Persons
24
25 Database (RPDB) contains information on all Ontario residents who are eligible for
26
27 health care coverage. To be eligible for health care coverage in Ontario residents
28
29 must be Canadian citizens, landed immigrants, or refugees, with Ontario as their
30
31 primary or permanent home, and must be present in Ontario for a minimum of 153
32
33 days over a 12-month period. Eligible Ontario residents are assigned a unique health
34
35 card number which permits access to health services available through a publicly
36
37 funded health care system. The RPDB was used to determine population size, sex, and
38
39 date of birth in the analysis. Ontario residents are represented in these databases by a
40
41 unique, encrypted identifier, which permits linkage across databases and provides
42
43 individual level HSU data. These databases are consistent with administrative data
44
45 used to estimate AGWs burden in previous studies (5, 15, 16).
46
47
48
49
50
51
52
53
54

55 56 57 **Data Sharing Statement** 58 59 60

1
2
3 This study used health administrative databases held at the Institute for Clinical and
4 Evaluative Sciences. Public deposition of ICES data is not permitted.
5
6
7

8 9 **Population**

10
11 Ontario is Canada's most populous and ethnically diverse province. We included all
12 Ontario residents 15 years and older with a valid health card number between April 1
13 2003 and March 31 2007, which included fiscal years 2003 to 2006 hereafter referred
14 to as simply year, based on the RPDB.
15
16
17
18
19

20 21 **Case Definition**

22
23 The outcome of interest was AGW HSU. We identified AGW HSU in the CIHI-DAD,
24 NACRS, and SDS databases using the International Classification of Diseases, 10th
25 revision (ICD-10) diagnostic code for AGWs, which is A630. There was no pre-existing
26 validated algorithm for identifying AGW cases in the OHIP database; therefore, we
27 identified codes with potential relevance to AGWs through the Ministry of Health and
28 Long Term Care (MOHLTC) Chapter 4 Claims Submissions (2003 and 2014 editions), the
29 Ontario Medical Association Section on General & Family Practice (SGFP) Common
30 Family Practice Codes (2011), the MOHLTC OHIP Schedule of Benefits for Physician
31 Services (2013), and the Practice Solutions (PSS) electronic medical record system as
32 an example of a common electronic medical record and billing system used in family
33 practice (S1). We reviewed the list of diagnostic and procedural codes in consultation
34 with physicians having experience in sexual and reproductive health services and
35 combined in algorithms for AGW case definitions. Smith et al report using similar OHIP
36 diagnostic and procedural codes in a recent analysis of AGWs in Ontario (18). We
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 conducted sensitivity analyses to identify the most probable case definition for AGWs .
4
5 The final algorithm to identify AGW HSU in OHIP was as follows: 099 only if billed with
6
7 Z117; or, 079 only if billed with Z117; or, 629 only if billed with Z117; or, Z549 or Z758;
8
9 or, Z733, Z736, or Z769 only in females; or, Z767 or Z701 only in males. Any of these
10
11 ten code combinations comprised of a diagnostic and/or procedural code constituted a
12
13 HSU for a case of AGWs.
14
15

16
17
18 We conducted descriptive analysis of AGW-related HSU by age group, sex, and fiscal
19
20 year. Age groups were designed to provide sufficient granularity in the ages
21
22 surrounding peak AGW HSU and incident AGWs, and to provide baseline data on age
23
24 groups targeted in the provincial HPV vaccination program as they age. Three-year age
25
26 groups were used for 15 to 44 year olds, 10-year age groups were used for 45 to 84
27
28 year olds, and a separate age group was used for individuals 85 years and older, to be
29
30 in line with the epidemiology of AGWs. Reported rates are either rates of total HSU for
31
32 AGWs i.e. every AGW-related health care visit; or, as rates of incident AGWs i.e. AGW
33
34 cases preceded by 12-months without an AGW visit divided by the number of health
35
36 card holders. This is similar to definitions used for incident cases in previous studies
37
38 (5, 15, 16,19). The first year of the study functioned to exclude prevalent cases when
39
40 estimating the rate of incident AGWs, thus, AGWs incidence data are available for
41
42 2004 to 2006, whereas total HSU data are available for 2003 to 2006. Rates reported
43
44 for multiple years are the average annual rates. Trends in AGWs were analyzed
45
46 separately for OHIP, NACRS, DAD, and SDS, as these databases represent different
47
48 health care settings. Rates are provided per 1000 population.
49
50
51
52
53
54
55

56 57 Sensitivity Analysis

58
59
60

1
2
3 One procedural code used in our AGW algorithm was for in-office chemical and/or
4
5 cryotherapy, Z117, in conjunction with a diagnostic code. Anogenital warts, however,
6
7 can be treated using other therapies including patient-administered topical agents.
8
9 Secular changes in the treatment of AGWs towards more patient-applied therapies
10
11 could skew AGW rates because there are no corresponding codes to capture such
12
13 treatment in administrative databases. To examine the potential impact of this, we
14
15 analyzed age and sex specific trends in Z117 and compared these results to AGW
16
17 trends using the full AGW case algorithm, and then with the OHIP code combinations
18
19 that included Z117.
20
21
22
23
24

25 This study was approved by the Research Ethics Board at Sunnybrook Health Sciences
26
27 Centre and the Ethics Review Board at Public Health Ontario. The Public Health
28
29 Ontario ERB approval number is 2014-056.01.
30
31
32

33 RESULTS

34
35
36 Combining physician office visits, SDS, hospitalizations, and ED visits for Ontario
37
38 residents 15 years and older between fiscal years 2003 and 2006, 51 436 individuals
39
40 had 123 247 health service visits for AGWs (Figure 1). Consistent with expected health
41
42 care patterns for AGWs, average annual HSU for AGWs varied across the databases
43
44 (hospitalizations: 0.01 per 1000; SDS: 0.23 per 1000; ED: 0.04 per 1000; and physician
45
46 office visits: 2.75 per 1000), as did the average annual rate of incident AGWs
47
48 (hospitalizations: 0.01 per 1000; SDS: 0.18 per 1000; ED: 0.03 per 1000; physician
49
50 office visits: 1.19 per 1000). As revealed by comparing the number of unique
51
52 individuals overall in all four databases (51 436) with the sum of the number of unique
53
54
55
56
57
58
59
60

1
2
3 individuals in each separate database (63 932), some individuals utilized more than
4 one type of health service for AGW diagnosis and/or treatment. From 2004 to 2006,
5 the total number of physician office visits for AGWs was just over double the
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

individuals in each separate database (63 932), some individuals utilized more than one type of health service for AGW diagnosis and/or treatment. From 2004 to 2006, the total number of physician office visits for AGWs was just over double the estimated number of new cases over the same period of time (data not shown). Same day surgery accounted for 7.6% of the visits, ED accounted for 1.3% of the visits, hospitalizations accounted for 0.4% of the visits, while physician office visits accounted for 90.7% of visits (Figure 1). As physician visits accounted for the vast majority of visits and had the highest number of unique individuals, the remainder of the analysis will focus on the OHIP database.

Incident HSU for AGWs

The rate of incident AGWs in physician offices during the study period varied with age and sex. Anogenital warts incidence peaked within the 21-23 age group for both females and males at rates of 3.74 per 1000 and 2.81 per 1000, respectively (Figure 2). In the 15 to 26 age groups, incidence was higher amongst females compared to males, but between the ages of 27 to 44 years, the reverse was true, followed by similar rates between the sexes among those 45 years of age and older. The supplementary content contains the average annual rate of incident AGWs for 2004 to 2006 from the ED, hospitalization, and SDS databases (S2).

Trends by age group and sex

For females in the 15-17 age group, the rate of incident AGWs decreased from 1.21 in 2004, to 1.01 in 2005, and 0.95 in 2006 (Figure 3). In contrast, the rate of incident AGWs increased in females in the 24-26 age group from 2.77 in 2004, to 2.94 in 2005,

1
2
3 to 3.02 in 2006. The rate of incident AGWs showed little fluctuation in males from
4
5 2004 to 2006, with the exception of males in the 21-23 age group, which changed from
6
7 2.77 in 2004, to 3.01 in 2005, to 2.66 in 2006. From 2004 to 2006, females represented
8
9 a larger proportion of the new AGW cases in Ontario, but comprised a similar
10
11 proportion of the total AGW-related HSU relative to males (data not shown).
12
13

14
15
16 From 2003 to 2006, the total HSU for AGWs captured by the physician office visits
17
18 peaked in both females and males in the 21-23 age group, at a rate of 9.34 per 1000
19
20 and 7.22 per 1000, respectively (Figure 4). Health service utilization for AGWs was
21
22 higher amongst females in the 15 to 26 age groups compared to males, but between
23
24 the 27 to 74 age bands, the reverse was true.
25
26
27

28 29 **Sensitivity Analysis**

30
31
32 To investigate whether secular changes in the treatment of AGWs towards more
33
34 patient-applied therapies could be skewing AGW rates we analyzed age and sex
35
36 specific trends in Z117 over the study period and compared these results to AGW
37
38 trends using the full AGW case algorithm, and then with the OHIP code combinations
39
40 that included Z117 for case identification. The results of the sensitivity analysis among
41
42 21-23 year old females is provided as this was the age of peak AGW incidence for
43
44 females (S3). The results revealed that Z117 age distribution and rates for 15-38 year
45
46 olds exhibited different rates and trends than those observed in our AGW cases, thus
47
48 our observed AGW trends were unlikely a reflection of trends in Z117 treatment or
49
50 coding practices.
51
52
53
54

55 56 57 **DISCUSSION**

1
2
3 This is the first population-based study of HSU for AGWs in Ontario, and was
4
5 conducted using individual-level health administrative data from April 1 2003 to March
6
7 31 2007. Similar to previous studies from other regions, incident AGWs peaked in
8
9 females in the 21-23 age group (5, 15, 16, 20). Although several previous studies
10
11 reported peak incidence in males occurring at an older age than females (5, 16, 20),
12
13 we found a similar age of peak incidence in males and females, which has been
14
15 reported, but less frequently (15).
16
17
18
19

20
21 The two-fold higher total number of health service visits compared with incident AGW
22
23 visits for cases from 2004 to 2006 likely reflects multiple treatments for a single
24
25 episode or recurrence of AGWs within the 12-month window. This difference may also
26
27 reflect the continued treatment of prevalent cases from the start of the study period,
28
29 which could contribute to total visits but not total new cases as the 12-month washout
30
31 removed prevalent cases.
32
33
34
35

36 The decreasing incidence of AGWs in females in the 15-17 year age band is important
37
38 to consider as this is the age group where potential HPV vaccine program impact will
39
40 be first observed and may complicate assessment of HPV vaccine program impact. The
41
42 HPV4 vaccine became available for private purchase after it was launched by Merck in
43
44 August 2006. It is possible the decreasing incidence in the 15-17 year age band reflects
45
46 the impact of privately purchased HPV4 vaccine, however, this study was unable to
47
48 investigate vaccine receipt at the individual level to explore this possibility.
49
50
51
52

53 Changes to cervical cancer screening policy may also account for the decrease in
54
55 AGWs in the 15-17 year age band because some cases of AGWs may be picked up
56
57
58
59
60

1
2
3 incidentally during a cervical screening. The Ontario Cervical Screening Program
4
5 (OCSP) was launched in June 2000 and recommended Pap smears for any female who
6
7 had been sexually active, with screening at one-year intervals, and after three normal
8
9 Pap smears, screening was recommended every two years. The recommendations
10
11 changed in 2005 to screening starting within three years of first sexual activity, with
12
13 screening recommended every two to three years after three consecutive normal Pap
14
15 smears. Thus, from 2005, Pap smears would have been conducted less frequently and
16
17 age of first Pap may have been later. These changes could impact the rate of AGW
18
19 diagnosis in females if the Pap smear procedure was a significant means of identifying
20
21 AGWs; unfortunately investigation of how changes to Pap smear policy relate to AGWs
22
23 diagnosis and treatment rates was beyond the scope of this study.
24
25
26
27
28
29

30 Relying on health administrative data does not capture undiagnosed and untreated
31
32 AGWs, thereby underestimating the true incidence of AGWs; although this would also
33
34 be a limitation if surveillance data were available. The OHIP database does not
35
36 capture AGW-related health visits to providers not captured by fee-for-service
37
38 remuneration models without shadow billing, including sexual health clinics, public
39
40 health clinics, and community health centres. The literature indicates that STI clinics
41
42 report higher rates of AGWs than general practices (21) and that certain populations
43
44 are more likely to utilize these types of services (22), including individuals without
45
46 valid health card numbers. Thus, the findings reported here are likely an
47
48 underestimate of incidence and HSU for AGWs in Ontario. As described in the
49
50 sensitivity analysis, we were unable to identify AGWs treated topically by the patient,
51
52 thus, such cases may be missing from the counts. Although the study period spans a
53
54
55
56
57
58
59
60

1
2
3 relatively short window of four years, the data may be impacted by changes to clinical
4
5 practices in terms of compensation, coding, treatment etc., which have not been
6
7 accounted for here. Conversely, this study is not limited by self-reporting.
8
9

10 Unlike cervical cancer, which develops over years, AGWs are an early indicator of HPV
11
12 transmission. The objective of our report was to provide a baseline of AGW
13
14 epidemiology in Ontario in the years leading up to the introduction of the publicly-
15
16 funded, female-targeted school-based HPV vaccination program. Subsequent studies
17
18 of AGW epidemiology in Ontario will build on this knowledge to assess the impact of
19
20 the vaccination program.
21
22
23
24

25 26 **Acknowledgements:**

27
28 This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which
29
30 is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care
31
32 (MOHLTC). The opinions, results and conclusions reported in this paper are those of
33
34 the authors and are independent from the funding sources. No endorsement by ICES or
35
36 the Ontario MOHLTC is intended or should be inferred.
37
38
39

40 41 **Competing interests:**

42
43
44 None.

45 46 47 **Funding:**

48
49
50 Funding was provided by Public Health Ontario.
51

52 53 54 **Ethics:**

1
2
3 This study was approved by the Research Ethics Board at Sunnybrook Health Sciences
4
5 Centre and the Ethics Review Board at Public Health Ontario, ERB approval 2014-
6
7 056.01.
8
9

10 11 **Contributorship Statement:**

12
13
14 SLD conceived of the study, participated in study design, data interpretation, and
15
16 writing of the manuscript. FMG participated in study design, data analysis and
17
18 interpretation, supervised the statistical analysis, and wrote the first draft of the
19
20 manuscript and revised drafts. CC had full access to the data and performed data
21
22 analysis. SEW provided clinical expertise, and participated in study design, data
23
24 interpretation, and writing of the manuscript. SD provided clinical expertise and
25
26 participated in data interpretation and writing of the manuscript. LCR participated in
27
28 study design, data analysis and interpretation, and writing of the manuscript.
29
30
31
32
33

34 **Key Messages Box**

- 35
36
37 • Anogenital warts are an early indicator of HPV transmission in a population
38
39 relative to cervical cancers, which take more time to develop.
- 40
41
42 • Anogenital warts incidence and health service utilization in Ontario peaked in
43
44 the 21-23 age group for both females and males.
- 45
46
47 • In the three years leading up to the Ontario HPV4 program, the sex and age
48
49 distribution of AGWs was found to be similar to other Canadian provinces before
50
51 widespread program implementation.
52
53
54
55

56 **References**

57
58
59
60

- 1
2
3 1. Winer, RL, Lee, SK, Hughes, JP, et al. Genital human papillomavirus infection:
4 incidence and risk factors in a cohort of female university students. *Am J Epidemiol*
5 2003;157(3),218-226.
6
7
- 8
9 2. Freitas AC, Mariz FC, Silva MA, et al. Human papillomavirus vertical transmission: review of
10 current data. *Clin Infect Dis* 2013;May;56(10):1451-6.
11
12
- 13 3. Nyitray AG, Iannacone MR. The epidemiology of human papillomaviruses. *Curr Probl*
14 *Dermatol* 2014;45:75-91.
15
16
- 17 4. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall
18 we vaccinate and screen? The international perspective. *Int J Cancer* 2004; Aug 20;111(2):278-
19 85.
20
21
22
23
- 24 5. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in
25 Canada. *Sex Transm Infect* 2009;Apr;85(2):111-5.
26
27
- 28 6. Wang KL, Jeng CJ, Yang YC, et al. The psychological impact of illness among women
29 experiencing human papillomavirus-related illness or screening interventions. *J Psychosom*
30 *Obstet Gynaecol* 2010; Mar;31(1):16-23.
31
32
33
- 34 7. Lynde C, Vender R, Bourcier M, et al. Clinical features of external genital warts. *J Cutan*
35 *Med Surg* 2013; Dec;17Suppl2:S55-60.
36
37
- 38 8. Richards S. An overview of genital warts. *Nurs Stand* 2014; Feb 12-18;28(24):46-50.
39
40
- 41 9. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of
42 human papillomavirus infections in a cohort of 290 US men. *J Infect Dis*
43 2008;Sep15;198(6):827-35.
44
45
46
- 47 10. Insinga RP, Dasbach EJ, Elbasha EH, et al. Incidence and duration of cervical human
48 papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple
49 analytic perspectives. *Cancer Epidemiol Biomarkers Prev* 2007;Apr;16(4):709-15.
50
51
52
- 53 11. Stone KM. Human papillomavirus infection and genital warts: update on epidemiology and
54 treatment. *Clin Infect Dis* 1995;Apr;20 Suppl1:S91-7.
55
56
57
58
59
60

- 1
2
3 12. The Canadian Guidelines on Sexually Transmitted Infections Treatment.
4 <http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php> Accessed July 2015.
5
6
7
8 13. Hariri S, Markowitz LE, Dunne EF, et al. Population impact of HPV vaccines: summary of
9 early evidence. *J Adolesc Health* 2013;Dec;53(6):679-82.
10
11
12 14. Garland SM. The Australian experience with the human papillomavirus vaccine. *Clin Ther*
13 2014;Jan1;36(1):17-23.
14
15
16 15. Kliewer EV, Demers AA, Elliott L, et al. Twenty-year trends in the incidence and
17 prevalence of diagnosed anogenital warts in Canada. *Sex Transm Dis* 2009; Jun;36(6):380-6.
18
19
20
21 16. Steben M, Ouhoumane N, Rodier C, et al. Temporal trends in genital warts among
22 individuals covered by the public prescription drug insurance plan in the province of Quebec,
23 Canada, from 1998 to 2007. *J Low Genit Tract Dis* 2013;Apr;17(2):147-53.
24
25
26
27 17. Chan, BT & Schultz, SE. Supply and utilization of general practitioner and family physician
28 services in Ontario. Institute for Clinical Evaluative Sciences. Toronto, ON: Institute for
29 Clinical Evaluative Sciences 2005. [http://www.ices.on.ca/Publications/Atlases-and-](http://www.ices.on.ca/Publications/Atlases-and-Reports/2005/Supply-and-utilization)
30 [Reports/2005/Supply-and-utilization](http://www.ices.on.ca/Publications/Atlases-and-Reports/2005/Supply-and-utilization) . Accessed July 2015.
31
32
33
34
35 18. Smith LM, Strumpf EC, Kaufman JS, et al. The early benefits of human papillomavirus
36 vaccination on cervical dysplasia and anogenital warts. *Pediatrics* 2015; May;135(5):e1131-40.
37
38
39
40 19. Camenga, DR, Dunne, EF, Desai, MM, et al. Incidence of Genital Warts in Adolescents and
41 Young Adults in an Integrated Health Care Delivery System in the United States Before Human
42 Papillomavirus Vaccine Recommendations. *Sexually Transm Dis*,2013;40(7),534-538.
43
44
45
46 20. Mikolajczyk RT, Kraut AA, Horn J, et al. Changes in incidence of anogenital warts
47 diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic
48 study. *Sex Transm Dis* 2013;Jan;40(1):28-31.
49
50
51
52 21. Xi, LF & Koutsky, LA. Epidemiology of genital human papillomavirus infections. *Bulletin*
53 *de l'Institut Pasteur*, 1997;95(3),161-178.
54
55
56 22. Brackbill, RM, Sternberg, MR, & Fishbein, M. Where do people go for treatment of
57 sexually transmitted diseases? *Family Planning Perspectives*, 1999;10-15.
58
59
60

Licence for Publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ and co-owners or contracting owning societies (where published by the BMJ on their behalf), and its Licensees to permit this article (if accepted) to be published in Sexually Transmitted Infections and any other BMJ products and to exploit all subsidiary rights, as set out in our licence.

FIGURE LEGENDS

Figure 1. Counts and rates of AGWs by data source for Ontario residents 15 years and older, with a valid health card number, fiscal years 2003 to 2006. Rates are average annual for indicated period of time.

¹ 2003 to 2006

² 2004-2006, with 2003 as a washout to exclude prevalent cases

Health service utilization, HSU

Figure 2. Average annual rate of incident AGWs captured by physician office visits, by sex and age group, fiscal years 2004 to 2006.

Figure 3. Annual incident AGWs captured by physician office visits, by fiscal year, sex, and age group, fiscal years 2004 to 2006.

1
2
3 Figure 4. Average annual health service utilization (HSU) for AGWs captured by
4 physician office visits, by sex and age group, fiscal years 2003 to 2006.
5
6
7


8
9 S1. Table of AGW-related diagnostic and procedural codes used by physician offices.
10

11
12 S2. Average annual rate of incident AGWs captured by hospitalizations (DAD)(a); same
13 day surgery (b); and emergency department visits (NACRS)(e), by sex and age group,
14 fiscal years 2004 to 2006.
15
16
17

18
19
20 S3. Sensitivity analysis of billing code for physician-administered, in-office chemical or
21 cryotherapy, Z117. Age distribution of HSU with code Z117 for fiscal year 2004 (a);
22 age-specific trends in code Z117 in females (b); age-specific trends in billing code
23 combinations that include Z117, for 21-23 year old females (c).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



33 Figure 1. Counts and rates of AGWs by data source for Ontario residents 15 years and older, with a valid
 34 health card number, fiscal years 2003 to 2006. Rates are average annual for the indicated period of time. ¹
 35 2003 to 2006, ² 2004 to 2006, 2003 as washout to exclude prevalent cases. HSU, health service utilization.
 36 254x190mm (96 x 96 DPI)




Figure 2. Average annual rate of incident AGWs captured by physician office visits, by sex and age group, fiscal years 2004 to 2006.
254x190mm (96 x 96 DPI)

ew only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Annual incident AGWs captured by physician office visits, by fiscal year, sex, and age group, fiscal years 2004 to 2006.
254x190mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 4. Average annual health service utilization (HSU) for AGWs captured by physician office visits, by sex and age group, fiscal years 2003 to 2006.
254x190mm (96 x 96 DPI)

ew only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Code	Description
ICD-10	
A630	Anogenital (venereal) warts
OHIP	
Diagnostic Codes	
099	venereal disease, TD, condyloma, Duchennes, herpes genitalis, chlamydia,
079	condyloma accuminata, rabies, viral disease, other viral disease, viral illness
629	Warts, venereal, other disorders, Other diseases or disorders not specified elsewhere-genital organs female, other disorders of female genital organs, condylomata, leukorrhoea
078	verruca(plantar wart), warts, all types, other viral disease, warts
K028	STD, BBD mgmt
Procedural Codes	
Z117	Chemical Rx wart (plantar, genital)
Z549	Digestive system surgical procedures: Rectum: Destruction: Fulguration of condylomata (local anaesthesia)
Z701	Male genital surgical procedures: Excision: condylomata (local anaesthesia)
Z733	Female genital surgical procedures: Excision: condylomata (chem or cryo surgery)
Z736	Female genital surgical procedures: Excision: condylomata (local anaesthesia, surgical excision OR electrodesiccation OR CO2 laser)
Z758	Digestive system surgical procedures: Rectum: Destruction: Fulguration of condylomata (general anaesthesia)
Z767	Male genital surgical procedures: Excision: condylomata (general anaesthesia)
Z769	Female genital surgical procedures: Excision: condylomata (general anaesthesia, surgical excision OR electrodesiccation OR CO2 laser)

S1. Table of AGW-related diagnostic and procedural codes used by physician offices.
254x190mm (96 x 96 DPI)



S2. Average annual rate of incident AGWs captured by hospitalizations (DAD)(a); same day surgery (b); and emergency department visits (NACRS) (e), by sex and age group, fiscal years 2004 to 2006. 254x190mm (96 x 96 DPI)



S3. Sensitivity analysis of billing code for physician-administered, in-office chemical or cryotherapy, Z117. Age distribution of HSU with code Z117 for fiscal year 2004 (a); age-specific trends in code Z117 in females (b); age-specific trends in billing code combinations that include Z117, for 21-23 year old females (c). 254x190mm (96 x 96 DPI)

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	
Objectives	3	State specific objectives, including any pre-specified hypotheses	
Methods			
Study design	4	Present key elements of study design early in the paper	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Health service utilization for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine program introduction: a retrospective longitudinal population-based study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-009914.R1
Article Type:	Research
Date Submitted by the Author:	04-Jan-2016
Complete List of Authors:	Guerra, Fiona; Public Health Ontario, Applied Immunization Research Rosella, Laura; University of Toronto, Dalla Lana School of Public Health; Public Health Ontario, Public Health Sciences Dunn, Sheila; University of Toronto, Family and Community Medicine; Women's College Hospital, Family and Community Medicine Wilson, Sarah; Public Health Ontario, Immunization and vaccine-preventable diseases; University of Toronto, Dalla Lana School of Public Health Chen, Cynthia; Public Health Ontario, Knowledge Services Deeks, Shelley; Public Health Ontario, Immunization and vaccine-preventable diseases; University of Toronto, Dalla Lana School of Public Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Sexual health, Public health, Health services research, Infectious diseases
Keywords:	EPIDEMIOLOGY, GENITOURINARY MEDICINE, Community gynaecology < GYNAECOLOGY, Epidemiology < INFECTIOUS DISEASES, SEXUAL MEDICINE

SCHOLARONE™
Manuscripts

1 Health service utilization for anogenital warts in Ontario, Canada prior to the human
2 papillomavirus (HPV) vaccine program introduction: a retrospective longitudinal population-
3 based study

4 Fiona M. Guerra¹, Laura C. Rosella^{1,2,3}, Sheila Dunn^{4,5}, Sarah E. Wilson^{1, 2,3}, Cynthia Chen¹,
5 Shelley L. Deeks^{1,2}

6 ¹Public Health Ontario, Toronto, ON, CA

7 ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, CA

8 ³Institute for Clinical Evaluative Sciences, Toronto, ON, CA

9 ⁴Department of Family and Community Medicine, University of Toronto, ON, CA

10 ⁵Women's College Hospital and Women's College Research Institute, Toronto, ON, CA

11 Corresponding author: Fiona M. Guerra, MPH, PhD

12 Postdoctoral fellow, Applied Immunization Research

13 Public Health Ontario

14 480 University Ave., Suite 300, Toronto, ON, M5G 1V2

15 Phone: (647) 260-7591

16 Fax: (647) 260-7600

17 fiona.guerra@gmail.com

18 Key Words: genital warts; anogenital warts; human papillomavirus; HPV; epidemiology of
19 genital warts; health service utilization

20 Word Count: 3223

1 ABSTRACT

2 **Objective:** Trends in occurrence of anogenital warts (AGWs) can provide early evidence of
3 human papillomavirus (HPV) vaccination program impact on preventing HPV infection and
4 HPV-induced lesions. The objective of this study was to provide a baseline of AGW
5 epidemiology in Ontario prior to the introduction of the publicly-funded school-based HPV
6 vaccination program in September 2007.

7 **Setting and Participants:** As a retrospective longitudinal population-based study, we used
8 health administrative data as a proxy to estimate incident AGWs and total health service
9 utilization (HSU) for AGWs for all Ontario residents 15 years and older with valid health cards
10 between April 1 2003 and March 31 2007.

11 **Outcome Measures:** The outcome of interest was AGW health care utilization identified using
12 the International Classification of Diseases, 10th revision (ICD-10) diagnostic code for AGWs,
13 as well as an algorithm for identifying AGW physician office visits in a database with a unique
14 system of diagnostic and procedural codes. An AGW case was considered incident if preceded
15 by 12 months without HSU for AGWs. Time trends by age group and sex were analyzed.

16 **Results:** Between fiscal years 2003 and 2006, we identified 123 247 health service visits for
17 AGWs by 51 436 Ontario residents 15 years and older. Incident AGWs peaked in females and
18 males in the 21-23 year age group, at 3.74 per 1000 and 2.81 per 1000, respectively. HSU for
19 AGWs peaked in both females and males within the 21-23 age group, at 9.34 per 1000 and 7.22
20 per 1000, respectively.

21 **Conclusions:** To our knowledge, this is the first population-based study of AGW incidence and
22 HSU in Ontario. The sex and age distribution of individuals with incident and prevalent AGWs

1
2
3 1 in Ontario was similar to that of other provinces before HPV vaccine program implementation
4
5 2 in Canada.
6
7

8 3 ARTICLE SUMMARY
9

- 10
11 4 • AGW is considered the first clinical endpoint to evaluate an HPV vaccination program. We
12 report the baseline of AGW epidemiology in Ontario-Canada's most populous and
13 ethnically diverse province- in the years leading up to the introduction of the publicly-
14 funded, female-targeted school-based HPV vaccination program.
15
16 7
17
18 8 • We used health administrative data to identify incident AGWs and health service
19 utilization (HSU) for AGWs for Ontario residents 15 years and older. These databases are
20 consistent with administrative data used to estimate AGW burden in previous studies.
21
22 9
23 10
24 11 • The databases capture only AGW-related health visits to providers working in
25 remuneration models that submit billing data to the province and exclude visits to some
26 sexual health clinics, public health clinics, and community health centres, nor does the
27 data capture undiagnosed and untreated AGWs. Thus, the data are an underestimate of
28 the true incidence of AGWs.
29
30 12
31 13
32 14
33 15
34 16 • The data may be impacted by changes to clinical practices in terms of compensation,
35 coding, treatment etc., which were not accounted for here.
36
37 17
38
39
40
41
42
43
44
45
46 18
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Most individuals will acquire human papillomavirus (HPV) at some point in their lifetime. HPV
2 can be transmitted by vaginal, anal, and oral sex, as well as non-penetrative sex including
3 digital-vaginal or skin-to-skin contact (1), and through vertical transmission (2). Although most
4 HPV infections are transient and resolve without treatment, HPV infection can lead to both
5 benign and cancerous conditions. At least 150 different HPV genotypes have been described,
6 with approximately 40 genotypes having tissue specificity for the anogenital region and oral
7 cavity (3). HPV-6 and -11 accounted for approximately 90% of anogenital warts (AGWs), while
8 HPV-16 and -18 accounted for approximately 70% of cervical cancers prior to vaccine
9 introduction (4). HPV is also associated with other anogenital cancers (vaginal, vulvar, penile,
10 anal canal) and a subset of head and neck squamous cell carcinomas. The licensing of
11 prophylactic HPV vaccines Gardasil® (referred to as HPV4 vaccine, targeting HPV types 6, 11,
12 16, and 18, by Merck & Co., Whitehouse Station, NJ USA) and Cervarix® (targeting HPV types
13 16 and 18, by GlaxoSmithKline Biologicals, Rixensart, Belgium) in countries around the world
14 starting in 2006 introduced the possibility of primary prevention for HPV-related malignancy
15 with both vaccines, and AGWs with HPV4 vaccine.

16 Also known as condylomata acuminata, AGWs appear as multiple, asymmetric epithelial
17 growths on the anogenital skin or mucous membranes. They can fluctuate in size and number,
18 and can be flat, papular, cauliflower-like or keratotic. Anogenital warts are associated with
19 significant costs to the health care system (5) and can cause substantial psychological distress
20 (6, 7), as well as pain and discomfort in some cases in the form of itching, discharge, burning,
21 or bleeding (8, 9). Approximately 70% of HPV-6/11 infections are cleared within 12 months
22 (10, 11), with 10-30% of AGW cases clearing spontaneously within three months (12).

23 Treatments used in Canada include topical therapies applied by a physician or the patient, or
24 physician administered ablative treatments such as cryotherapy, electrosurgery, CO2 laser, or
25 surgical excision (13).

1 Trends in health service utilization (HSU) for AGWs can provide an early indication of the
2 impact of Ontario's HPV vaccine program in preventing HPV infection, by providing valuable
3 information on the burden of AGWs pre- and post-vaccine program implementation. Other
4 countries with HPV vaccination programs have begun reporting significant decreases in the
5 incidence of AGWs in females targeted for vaccination since the introduction of their
6 programs (reviewed by 14, 15). Several Canadian provinces have conducted baseline studies of
7 AGW epidemiology in anticipation of evaluating HPV vaccine program impact, reporting peak
8 incidence rates for males and females ranging from 3.03 to 3.92/1000 population and 3.38 to
9 4.66/1000 population, respectively (5, 16, 17).

10 The objective of our report is to provide a baseline of AGW epidemiology in Ontario in the
11 years leading up to the introduction of the publicly-funded, female-targeted school-based HPV
12 vaccination program, which was introduced in the fall of 2007.

13 **METHODS**

14 **Databases**

15 Neither AGWs nor HPV infection are reportable diseases in Ontario, therefore there are no
16 surveillance data to derive incidence and prevalence. Data are available on AGW-related HSU
17 in Ontario through a variety of health administrative databases. The Ontario Health Insurance
18 Plan (OHIP) database captures fee-for-service claims made by Ontario physicians, and
19 represents claims from approximately 98% of physicians in the province (18). The OHIP
20 database was used to identify physician visits for AGWs using a combination of diagnostic and
21 procedural codes. The Canadian Institute of Health Information (CIHI)-Discharge Abstract
22 Database (DAD) was used to identify hospitalizations for AGWs. The CIHI National Ambulatory
23 Care Reporting System (NACRS) covers hospital and community-based ambulatory care
24 services, and was used to identify emergency department (ED) visits for AGWs. The Same-Day-

1
2
3 1 Surgery (SDS) database was used to identify same day surgeries and procedures for AGWs. The
4
5 2 Registered Persons Database (RPDB) contains information on all Ontario residents who are
6
7 3 eligible for health care coverage. To be eligible for health care coverage in Ontario residents
8
9 4 must be Canadian citizens, landed immigrants, or refugees, with Ontario as their primary or
10
11 5 permanent home, and must be present in Ontario for a minimum of 153 days over a 12-month
12
13 6 period. Eligible Ontario residents are assigned a unique health card number which permits
14
15 7 access to health services available through a publicly funded health care system. The RPDB
16
17 8 was used to determine population size, sex, and date of birth in the analysis. These datasets
18
19 9 were linked using unique encoded identifiers and analyzed at the Institute for Clinical
20
21 10 Evaluative Sciences. These data sources are consistent with administrative data used to
22
23 11 estimate AGWs burden in previous studies (5, 16, 17).
24
25
26
27

28 12 **Data Sharing Statement**

29
30
31 13 This study used health administrative databases held at the Institute for Clinical and
32
33 14 Evaluative Sciences. Public deposition of ICES data is not permitted.
34
35

36 15 **Population**

37
38
39 16 Ontario is Canada's most populous and ethnically diverse province. We included all Ontario
40
41 17 residents 15 years and older with a valid health card number between April 1 2003 and March
42
43 18 31 2007, which included fiscal years 2003 to 2006 hereafter referred to as simply year, based
44
45 19 on the RPDB.
46
47
48

49 20 **Case Definition**

50
51
52 21 The outcome of interest was AGW HSU. We identified AGW HSU in the CIHI-DAD, NACRS, and
53
54 22 SDS databases using the International Classification of Diseases, 10th revision (ICD-10)
55
56 23 diagnostic code for AGWs, which is A630. There was no pre-existing validated algorithm for
57
58
59
60

1 identifying AGW cases in the OHIP database; therefore, we identified codes with potential
2 relevance to AGWs through the Ministry of Health and Long Term Care (MOHLTC) Chapter 4
3 Claims Submissions (2003 and 2014 editions), the Ontario Medical Association Section on
4 General & Family Practice (SGFP) Common Family Practice Codes (2011), the MOHLTC OHIP
5 Schedule of Benefits for Physician Services (2013), and the Practice Solutions (PSS) electronic
6 medical record system as an example of a common electronic medical record and billing
7 system used in family practice (supplementary figure 1). We reviewed the list of diagnostic
8 and procedural codes in consultation with physicians having experience in sexual and
9 reproductive health services and combined in algorithms for AGW case definitions. Smith et al
10 report using similar OHIP diagnostic and procedural codes in a recent analysis of AGWs in
11 Ontario (19). We conducted sensitivity analyses to identify the most probable case definition
12 for AGWs. The final algorithm to identify AGW HSU in OHIP was as follows: 099 only if billed
13 with Z117; or, 079 only if billed with Z117; or, 629 only if billed with Z117; or, Z549 or Z758;
14 or, Z733, Z736, or Z769 only in females; or, Z767 or Z701 only in males. Any of these ten code
15 combinations comprised of a diagnostic and/or procedural code constituted a HSU for a case
16 of AGWs.

17 We conducted descriptive analysis of AGW-related HSU by age group, sex, and fiscal year. Age
18 groups were designed to provide sufficient granularity in the ages surrounding peak AGW HSU
19 and incident AGWs, and to provide baseline data on age groups targeted in the provincial HPV
20 vaccination program as they age. Three-year age groups were used for 15 to 44 year olds, 10-
21 year age groups were used for 45 to 84 year olds, and a separate age group was used for
22 individuals 85 years and older, to be in line with the epidemiology of AGWs. Reported rates
23 are either rates of total HSU for AGWs i.e. every AGW-related health care visit; or, as rates of
24 incident AGWs i.e. AGW cases preceded by 12-months without an AGW visit divided by the
25 number of health card holders. This is similar to definitions used for incident cases in previous

1 studies (5, 16, 17, 20). The first year of the study functioned to exclude prevalent cases when
2 estimating the rate of incident AGWs, thus, AGWs incidence data are available for 2004 to
3 2006, whereas total HSU data are available for 2003 to 2006. Rates reported for multiple years
4 are the average annual rates. Trends in AGWs were analyzed separately for OHIP, NACRS,
5 DAD, and SDS, as these databases represent different health care settings. Rates are provided
6 per 1000 population.

7 **Sensitivity Analysis**

8 One procedural code used in our AGW algorithm was for in-office chemical and/or
9 cryotherapy, Z117, in conjunction with a diagnostic code. Anogenital warts, however, can be
10 treated using other therapies including patient-administered topical agents. Secular changes
11 in the treatment of AGWs towards more patient-applied therapies could skew AGW rates
12 because there are no corresponding codes to capture such treatment in administrative
13 databases. To examine the potential impact of this, we analyzed age and sex specific trends
14 in Z117 and compared these results to AGW trends using the full AGW case algorithm, and
15 then with the OHIP code combinations that included Z117.

16 This study was approved by the Institutional Review Boards at Sunnybrook Health Sciences
17 Centre and Public Health Ontario in Toronto, Canada. The Public Health Ontario ERB approval
18 number is 2014-056.01.

19 **RESULTS**

20 Combining physician office visits, SDS, hospitalizations, and ED visits for Ontario residents 15
21 years and older between fiscal years 2003 and 2006, 51 436 individuals had 123 247 health
22 service visits for AGWs (Figure 1). Consistent with expected health care patterns for AGWs,
23 average annual HSU for AGWs varied across the databases (hospitalizations: 0.01 per 1000;

1 SDS: 0.23 per 1000; ED: 0.04 per 1000; and physician office visits: 2.74 per 1000), as did the
2 average annual rate of incident AGWs (hospitalizations: 0.01 per 1000; SDS: 0.18 per 1000; ED:
3 0.03 per 1000; physician office visits: 1.19 per 1000). As revealed by comparing the number of
4 unique individuals overall in all four databases (51 436) with the sum of the number of unique
5 individuals in each separate database (63 932), some individuals utilized more than one type
6 of health service for AGW diagnosis and/or treatment. From 2004 to 2006, the total number of
7 physician office visits for AGWs was just over double the estimated number of new cases over
8 the same period of time (data not shown). Same day surgery accounted for 7.6% of the visits,
9 ED accounted for 1.3% of the visits, hospitalizations accounted for 0.4% of the visits, while
10 physician office visits accounted for 90.7% of visits (Figure 1). As physician visits captured in
11 the OHIP database accounted for the vast majority of visits and had the highest number of
12 unique individuals, the analysis will focus primarily on the OHIP database.

13 **AGW incidence**

14 The rate of incident AGWs during the study period varied with age and sex. Females in the 15-
15 38 age group were more frequently diagnosed with AGWs in hospitals and SDS than males in
16 the same age group (Figure 2 a, b). AGW incidence rates were more similar between sexes for
17 AGWs diagnosed in ED, however AGW incidence was higher in females < 21 years and males
18 21-26 years compared to the opposite sex of the same age groups (Figure 2 c). The rate of
19 incident AGWs in physician offices also varied with age and sex. Anogenital warts incidence
20 peaked within the 21-23 age group for both females and males at rates of 3.74 per 1000 and
21 2.81 per 1000, respectively (Figure 3). In the 15 to 26 age groups, incidence was higher
22 amongst females compared to males, but between the ages of 27 to 41 years, the reverse was
23 true, followed by similar rates between the sexes among those 42 years of age and older.

24 **Trends by age group and sex**

1 For females in the 15-17 age group, the rate of incident AGWs decreased from 1.21 in 2004, to
2 1.01 in 2005, and 0.95 in 2006 (Figure 4). In contrast, the rate of incident AGWs increased in
3 females in the 24-26 age group from 2.77 in 2004, to 2.94 in 2005, to 3.02 in 2006. The rate of
4 incident AGWs showed little fluctuation in males from 2004 to 2006, with the exception of
5 males in the 21-23 age group, which changed from 2.77 in 2004, to 3.01 in 2005, to 2.66 in
6 2006. From 2004 to 2006, females represented a larger proportion of the new AGW cases in
7 Ontario, but comprised a similar proportion of the total AGW-related HSU relative to males
8 (data not shown).

9 From 2003 to 2006, the total HSU for AGWs captured by the physician office visits peaked in
10 both females and males in the 21-23 age group, at a rate of 9.34 per 1000 and 7.22 per 1000,
11 respectively (Figure 5). Health service utilization for AGWs was higher amongst females in the
12 15 to 26 age groups compared to males, but between the 27 to 74 age bands, the reverse was
13 true.

14 **Sensitivity Analysis**

15 To investigate whether secular changes in the treatment of AGWs towards more patient-
16 applied therapies could be skewing AGW rates we analyzed age and sex specific trends in Z117
17 over the study period and compared these results to AGW trends using the full AGW case
18 algorithm, and then with the OHIP code combinations that included Z117 for case
19 identification. The results of the sensitivity analysis among 21-23 year old females is provided
20 as this was the age of peak AGW incidence for females (supplementary figure 2a, 2b, 2c). The
21 results revealed that Z117 age distribution and rates for 15-38 year olds exhibited different
22 rates and trends than those observed in our AGW cases, thus our observed AGW trends were
23 unlikely a reflection of trends in Z117 treatment or coding practices.

24 **DISCUSSION**

1 This is the first population-based study of HSU for AGWs in Ontario, and was conducted using
2 individual-level health administrative data from April 1 2003 to March 31 2007. Similar to
3 previous studies from other regions, incident AGWs peaked in females in the 21-23 age group
4 (5, 16, 17). Although several previous studies reported peak incidence in males occurring at an
5 older age than females (5, 17, 21), we found a similar age of peak incidence in males and
6 females, which has been reported, but less frequently (16). However, incidence in males
7 remained stable from the 21-23 and 24-26 age groups (2.81/1000 and 2.79/1000,
8 respectively), thus peak incidence spanned the 21-26 age group in males (Figure 3).

9 The two-fold higher total number of health service visits compared with incident AGW visits
10 for cases from 2004 to 2006 likely reflects multiple treatments for a single episode or
11 recurrence of AGWs within the 12-month window. This difference may also reflect the
12 continued treatment of prevalent cases from the start of the study period, which could
13 contribute to total visits but not total new cases as the 12-month washout removed prevalent
14 cases from the estimation of new cases.

15 The decreasing incidence of AGWs in females in the 15-17 year age band is important to
16 consider as this is the age group where potential HPV vaccine program impact will be first
17 observed and may complicate future assessment of HPV vaccine program impact.

18 Changes to cervical cancer screening policy may account for the decrease in AGWs in the 15-
19 17 year age band because some cases of AGWs may be picked up incidentally during a cervical
20 screening. The Ontario Cervical Screening Program (OCSP) was launched in June 2000 and
21 recommended Pap smears for any female who had been sexually active, with screening at
22 one-year intervals, and after three normal Pap smears, screening was recommended every
23 two years. The recommendations changed in 2005 to screening starting within three years of
24 first sexual activity, with screening recommended every two to three years after three

1 consecutive normal Pap smears. Thus, from 2005, Pap smears would have been conducted less
2 frequently and age of first Pap may have been later. These changes could impact the rate of
3 AGW diagnosis in females if the Pap smear procedure was a significant means of identifying
4 AGWs; unfortunately investigation of how changes to Pap smear policy relate to AGWs
5 diagnosis and treatment rates was beyond the scope of this study.

6 The observation that females are more frequently diagnosed with AGWs in hospitals and SDS
7 settings than males likely reflects gynecological and pregnancy-related services rendered in
8 these settings, which presents the opportunity for AGW diagnosis. This is supported by the
9 observation that the frequency of AGW visits in these sites is much higher for females of
10 reproductive age (late teens to late 30's) compared to males of the same age, whereas there
11 is little difference between the sexes beyond 39 years of age. The same argument can be
12 made for physician office visits, where females also seek reproductive health services. The
13 higher rate of AGW diagnosis in ED in the male 21-26 age group compared to females of the
14 same age is interesting and may reflect sex differences in health-seeking behaviour in Ontario
15 more generally and requires further study.

16 Relying on health administrative data does not capture undiagnosed and untreated AGWs,
17 thereby underestimating the true incidence of AGWs; although this would also be a limitation
18 if surveillance data were available. The OHIP database captures only AGW-related health visits
19 to providers working in remuneration models that submit billing data and excludes visits to
20 some sexual health clinics, public health clinics, and community health centres. The literature
21 indicates that STI clinics report higher rates of AGWs than general practices and that certain
22 populations are more likely to utilize these types of services (22, 23), including individuals
23 without valid health card numbers. Thus, the findings reported here are likely an
24 underestimate of incidence and HSU for AGWs in Ontario. As described in the sensitivity
25 analysis, we were unable to identify AGWs treated topically by the patient, thus, such cases

1
2
3 1 may be missing from the counts. Although the study period spans a relatively short window of
4
5 2 four years, the data may be impacted by changes to clinical practices in terms of
6
7 3 compensation, coding, treatment etc., which have not been accounted for here. Conversely,
8
9 4 this study is not limited by self-reporting.

10
11
12 5 Unlike cervical cancer, which develops over years, AGWs are an early indicator of HPV
13
14 6 transmission. The objective of our report was to provide a baseline of AGW epidemiology in
15
16 7 Ontario in the years leading up to the introduction of the publicly-funded, female-targeted
17
18 8 school-based HPV vaccination program. Subsequent studies of AGW epidemiology in Ontario
19
20 9 will build on this knowledge to assess the impact of the vaccination program.

21 22 23 24 10 **Acknowledgements:**

25
26
27 11 This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is
28
29 12 funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC).
30
31 13 The opinions, results and conclusions reported in this paper are those of the authors and are
32
33 14 independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is
34
35 15 intended or should be inferred. Parts of this material are based on data and information
36
37 16 compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements
38
39 17 expressed herein are those of the author, and not necessarily those of CIHI.
40
41
42 18

43 44 19 **Competing interests:**

45
46
47 20 None.

48 49 50 21 **Funding:**

51
52
53 22 Funding was provided by Public Health Ontario.

54 55 56 23 **Ethics:**

57
58
59
60

1 This study was approved by the Research Ethics Board at Sunnybrook Health Sciences Centre
2 and the Ethics Review Board at Public Health Ontario, ERB approval 2014-056.01.

3 **Contributorship Statement:**

4 SLD conceived of the study, participated in study design, data interpretation, and writing of
5 the manuscript. FMG participated in study design, data analysis and interpretation, supervised
6 the statistical analysis, and wrote the first draft of the manuscript and revised drafts. CC had
7 full access to the data and performed data analysis. SEW provided clinical expertise, and
8 participated in study design, data interpretation, and writing of the manuscript. SD provided
9 clinical expertise and participated in data interpretation and writing of the manuscript. LCR
10 participated in study design, data analysis and interpretation, and writing of the manuscript.

11 **Data sharing:**

12 No additional data available.

13 **Key Messages Box**

- 14 • Anogenital warts are an early indicator of HPV transmission in a population relative to
15 cervical cancers, which take more time to develop.
- 16 • Anogenital warts incidence and health service utilization in Ontario peaked in the 21-
17 23 age group for both females and males.
- 18 • In the three years leading up to the Ontario HPV4 program, the sex and age
19 distribution of AGWs was found to be similar to other Canadian provinces before
20 widespread program implementation.

22 **References**

- 1 1. Winer, RL, Lee, SK, Hughes, JP, et al. Genital human papillomavirus infection:
2 incidence and risk factors in a cohort of female university students. *Am J Epidemiol*
3 2003;157(3),218-226.
- 4 2. Freitas AC, Mariz FC, Silva MA, et al. Human papillomavirus vertical transmission: review of
5 current data. *Clin Infect Dis* 2013;May;56(10):1451-6.
- 6 3. Nyitray AG, Iannacone MR. The epidemiology of human papillomaviruses. *Curr Probl*
7 *Dermatol* 2014;45:75-91.
- 8 4. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall
9 we vaccinate and screen? The international perspective. *Int J Cancer* 2004; Aug 20;111(2):278-
10 85.
- 11 5. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in
12 Canada. *Sex Transm Infect* 2009;Apr;85(2):111-5.
- 13 6. Wang KL, Jeng CJ, Yang YC, et al. The psychological impact of illness among women
14 experiencing human papillomavirus-related illness or screening interventions. *J Psychosom*
15 *Obstet Gynaecol* 2010; Mar;31(1):16-23.
- 16 7. Drolet, M. et al. The impact of anogenital warts on health-related quality of life: a 6-month
17 prospective study. *Sexually transmitted diseases*, 2011, 38(10) :949-956.
- 18 8. Lynde C, Vender R, Bourcier M, et al. Clinical features of external genital warts. *J Cutan*
19 *Med Surg* 2013; Dec;17Suppl2:S55-60.
- 20 9. Richards S. An overview of genital warts. *Nurs Stand* 2014; Feb 12-18;28(24):46-50.
- 21 10. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of
22 human papillomavirus infections in a cohort of 290 US men. *J Infect Dis*
23 2008;Sep15;198(6):827-35.
- 24 11. Insinga RP, Dasbach EJ, Elbasha EH, et al. Incidence and duration of cervical human
25 papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple
26 analytic perspectives. *Cancer Epidemiol Biomarkers Prev* 2007;Apr;16(4):709-15.
- 27 12. Stone KM. Human papillomavirus infection and genital warts: update on epidemiology and
28 treatment. *Clin Infect Dis* 1995;Apr;20 Suppl1:S91-7.

- 1
2
3 1 13. The Canadian Guidelines on Sexually Transmitted Infections Treatment. [http://www.phac-](http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php)
4 [aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php](http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php) Accessed July 2015.
5
6
7 3 14. Hariri S, Markowitz LE, Dunne EF, et al. Population impact of HPV vaccines: summary of
8 early evidence. *J Adolesc Health* 2013;Dec;53(6):679-82.
9 4
10 5 15. Garland SM. The Australian experience with the human papillomavirus vaccine. *Clin Ther*
11 2014;Jan1;36(1):17-23.
12 6
13 7 16. Kliewer EV, Demers AA, Elliott L, et al. Twenty-year trends in the incidence and
14 prevalence of diagnosed anogenital warts in Canada. *Sex Transm Dis* 2009; Jun;36(6):380-
15 6.
16 8
17 9
18 10 17. Steben M, Ouhoumane N, Rodier C, et al. Temporal trends in genital warts among
19 individuals covered by the public prescription drug insurance plan in the province of
20 Quebec, Canada, from 1998 to 2007. *J Low Genit Tract Dis* 2013;Apr;17(2):147-53.
21 11
22 12 18. Chan, BT & Schultz, SE. Supply and utilization of general practitioner and family physician
23 services in Ontario. Institute for Clinical Evaluative Sciences. Toronto, ON: Institute for
24 Clinical Evaluative Sciences 2005. [http://www.ices.on.ca/Publications/Atlases-and-](http://www.ices.on.ca/Publications/Atlases-and-Reports/2005/Supply-and-utilization)
25 [Reports/2005/Supply-and-utilization](http://www.ices.on.ca/Publications/Atlases-and-Reports/2005/Supply-and-utilization) . Accessed July 2015.
26 14
27 15
28 16
29 17 19. Smith LM, Strumpf EC, Kaufman JS, et al. The early benefits of human papillomavirus
30 vaccination on cervical dysplasia and anogenital warts. *Pediatrics* 2015; May;135(5):e1131-
31 40.
32 18
33 19
34 20 20. Camenga, DR, Dunne, EF, Desai, MM, et al. Incidence of Genital Warts in Adolescents and
35 Young Adults in an Integrated Health Care Delivery System in the United States Before
36 Human Papillomavirus Vaccine Recommendations. *Sexually Transm Dis*,2013;40(7),534-
37 538.
38 21
39 22
40 23
41 24 21. Mikolajczyk RT, Kraut AA, Horn J, et al. Changes in incidence of anogenital warts
42 diagnoses after the introduction of human papillomavirus vaccination in Germany-an
43 ecologic study. *Sex Transm Dis* 2013;Jan;40(1):28-31.
44 25
45 26
46 27 22. Xi, LF & Koutsky, LA. Epidemiology of genital human papillomavirus infections. *Bulletin de*
47 *l'Institut Pasteur*, 1997;95(3),161-178.
48 28
49 29
50 30 23. Brackbill, RM, Sternberg, MR, & Fishbein, M. Where do people go for treatment of sexually
51 transmitted diseases? *Family Planning Perspectives*, 1999;10-15.
52 31
53 32
54
55
56
57
58
59
60

Licence for Publication

1 The Corresponding Author has the right to grant on behalf of all authors and does grant on
2 behalf of all authors, an exclusive license (or non-exclusive for government employees) on a
3 worldwide basis to the BMJ and co-owners or contracting owning societies (where published by
4 the BMJ on their behalf), and its Licensees to permit this article (if accepted) to be published
5 in Sexually Transmitted Infections and any other BMJ products and to exploit all subsidiary
6 rights, as set out in our license.

7

8 **FIGURE LEGENDS**

9 Figure 1. Counts and rates of AGWs by data source for Ontario residents 15 years and older,
10 with a valid health card number, fiscal years 2003 to 2006. Rates are average annual for
11 indicated period of time.

12 ¹ 2003 to 2006

13 ² 2004-2006, with 2003 as a washout to exclude prevalent cases

14 Health service utilization, HSU

15 Figure 2. Average annual rate of incident AGWs captured by hospitalizations (DAD)(a); same
16 day surgery (b); and emergency department visits (NACRS)(c), by sex and age group, fiscal
17 years 2004 to 2006.

18 Figure 3. Average annual rate of incident AGWs captured by physician office visits, by sex and
19 age group, fiscal years 2004 to 2006.

20 Figure 4. Annual incident AGWs captured by physician office visits, by fiscal year, sex, and age
21 group, fiscal years 2004 to 2006.

- 1
2
3 1 Figure 5. Average annual health service utilization (HSU) for AGWs captured by physician
4 office visits, by sex and age group, fiscal years 2003 to 2006.
5
6 2
7
8 3 Supplementary figure 1. Table of AGW-related diagnostic and procedural codes used by
9 physician offices.
10
11 4
12
13 5 Supplementary figure 2a. Sensitivity analysis of billing code for physician-administered, in-
14 office chemical or cryotherapy, Z117. Age distribution of HSU with code Z117 for fiscal year
15 6
16 2004.
17 7
18
19 8 Supplementary figure 2b. Age-specific trends in code Z117 in females.
20
21 9
22 23
24 9 Supplementary figure 2c. Age-specific trends in billing code combinations that include Z117,
25 10
26 for 21-23 year old females.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Counts and rates of AGWs by data source for Ontario residents 15 years and older, with a valid health card number, fiscal years 2003 to 2006. Rates are average annual for indicated period of time.

1 2003 to 2006

2 2004-2006, with 2003 as a washout to exclude prevalent cases

Health service utilization, HSU

215x120mm (300 x 300 DPI)




Figure 2. Average annual rate of incident AGWs captured by hospitalizations (DAD)(a); same day surgery (b); and emergency department visits (NACRS)(c), by sex and age group, fiscal years 2004 to 2006. 173x130mm (300 x 300 DPI)




Figure 3. Average annual rate of incident AGWs captured by physician office visits, by sex and age group, fiscal years 2004 to 2006.
142x102mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Annual incident AGWs captured by physician office visits, by fiscal year, sex, and age group, fiscal years 2004 to 2006.
173x109mm (300 x 300 DPI)

Review only





Figure 5. Average annual health service utilization (HSU) for AGWs captured by physician office visits, by sex and age group, fiscal years 2003 to 2006.
148x103mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Code	Description
ICD-10	
A630	
OHIP	
Diagnostic Codes	
099	venereal disease, TD, condyloma, Duchennes, herpes genitalis, chlamydia,
079	condyloma accuminata, rabies, viral disease, other viral disease, viral illness
629	Warts, venereal, other disorders, Other diseases or disorders not specified elsewhere-genital organs female, other disorders of female genital organs, condylomata, leukorrhea
078	verruca(plantar wart), warts, all types, other viral disease, warts
K028	STD, BBD mgmt
Procedural Codes	
Z117	Chemical Rx wart (plantar, genital)
Z549	Digestive system surgical procedures: Rectum: Destruction: Fulguration of condylomata (local anaesthesia)
Z701	Male genital surgical procedures: Excision: condylomata (local anaesthesia)
Z733	Female genital surgical procedures: Excision: condylomata (chem or cryo surgery)
Z736	Female genital surgical procedures: Excision: condylomata (local anaesthesia, surgical excision OR electrodesiccation OR CO2 laser)
Z758	Digestive system surgical procedures: Rectum: Destruction: Fulguration of condylomata (general anaesthesia)
Z767	Male genital surgical procedures: Excision: condylomata (general anaesthesia)
Z769	Female genital surgical procedures: Excision: condylomata (general anaesthesia, surgical excision OR electrodesiccation OR CO2 laser)

Supplementary figure 1. Table of AGW-related diagnostic and procedural codes used by physician offices.
173x163mm (300 x 300 DPI)



Supplementary figure 2. Sensitivity analysis of billing code for physician-administered, in-office chemical or cryotherapy, Z117. Age distribution of HSU with code Z117 for fiscal year 2004 (a); age-specific trends in code Z117 in females (b); age-specific trends in billing code combinations that include Z117, for 21-23 year old females (c).
173x104mm (300 x 300 DPI)

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a	Identify the report as a protocol of a systematic review See Page 1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number N/A
Authors:		
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author See Page 1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review See Page 14
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments N/A
Support:		
Sources	5a	Indicate sources of financial or other support for the review See Page 14
Sponsor	5b	Provide name for the review funder and/or sponsor See Page 14
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol See Page 14
INTRODUCTION		
Rationale	6	Describe the rationale for the review in the context of what is already known See Pages 4 & 5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) See Page 5
METHODS		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review N/A
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage See Pages 5-8
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated N/A
Study records:		
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review See Pages 5 & 6

Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	N/A
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms done independently, in duplicate), any processes for obtaining and confirming data from investigators	N/A
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	See Pages 5-8
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	N/A
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	N/A
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	N/A
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	See Page 8
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	N/A
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	N/A
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	N/A

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

Health service utilization for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine program introduction: a retrospective longitudinal population-based study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-009914.R2
Article Type:	Research
Date Submitted by the Author:	14-Feb-2016
Complete List of Authors:	Guerra, Fiona; Public Health Ontario, Applied Immunization Research Rosella, Laura; University of Toronto, Dalla Lana School of Public Health; Public Health Ontario, Public Health Sciences Dunn, Sheila; University of Toronto, Family and Community Medicine; Women's College Hospital, Family and Community Medicine Wilson, Sarah; Public Health Ontario, Immunization and vaccine-preventable diseases; University of Toronto, Dalla Lana School of Public Health Chen, Cynthia; Public Health Ontario, Knowledge Services Deeks, Shelley; Public Health Ontario, Immunization and vaccine-preventable diseases; University of Toronto, Dalla Lana School of Public Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Sexual health, Public health, Health services research, Infectious diseases
Keywords:	EPIDEMIOLGY, GENITOURINARY MEDICINE, Community gynaecology < GYNAECOLOGY, Epidemiology < INFECTIOUS DISEASES, SEXUAL MEDICINE

SCHOLARONE™
Manuscripts

1 Health service utilization for anogenital warts in Ontario, Canada prior to the human
2 papillomavirus (HPV) vaccine program introduction: a retrospective longitudinal population-
3 based study

4 Fiona M. Guerra¹, Laura C. Rosella^{1,2,3}, Sheila Dunn^{4,5}, Sarah E. Wilson^{1, 2,3}, Cynthia Chen¹,
5 Shelley L. Deeks^{1,2}

6 ¹Public Health Ontario, Toronto, ON, CA

7 ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, CA

8 ³Institute for Clinical Evaluative Sciences, Toronto, ON, CA

9 ⁴Department of Family and Community Medicine, University of Toronto, ON, CA

10 ⁵Women's College Hospital and Women's College Research Institute, Toronto, ON, CA

11 Corresponding author: Fiona M. Guerra, MPH, PhD

12 Postdoctoral fellow, Applied Immunization Research

13 Public Health Ontario

14 480 University Ave., Suite 300, Toronto, ON, M5G 1V2

15 Phone: (647) 260-7591

16 Fax: (647) 260-7600

17 fiona.guerra@gmail.com

18 Key Words: genital warts; anogenital warts; human papillomavirus; HPV; epidemiology of
19 genital warts; health service utilization

20 Word Count: 3260

1
2
3 1 **ABSTRACT**
4
5

6 2 **Objective:** Trends in occurrence of anogenital warts (AGWs) can provide early evidence of
7
8 3 human papillomavirus (HPV) vaccination program impact on preventing HPV infection and
9
10 4 HPV-induced lesions. The objective of this study was to provide a baseline of AGW
11
12 5 epidemiology in Ontario prior to the introduction of the publicly-funded school-based HPV
13
14 6 vaccination program in September 2007.
15
16

17
18 7 **Setting and Participants:** As a retrospective longitudinal population-based study, we used
19
20 8 health administrative data as a proxy to estimate incident AGWs and total health service
21
22 9 utilization (HSU) for AGWs for all Ontario residents 15 years and older with valid health cards
23
24 10 between April 1 2003 and March 31 2007.
25
26

27
28 11 **Outcome Measures:** The outcome of interest was AGW health care utilization identified using
29
30 12 the International Classification of Diseases, 10th revision (ICD-10) diagnostic code for AGWs,
31
32 13 as well as an algorithm for identifying AGW physician office visits in a database with a unique
33
34 14 system of diagnostic and procedural codes. An AGW case was considered incident if preceded
35
36 15 by 12 months without HSU for AGWs. Time trends by age group and sex were analyzed.
37
38

39
40 16 **Results:** Between fiscal years 2003 and 2006, we identified 123 247 health service visits for
41
42 17 AGWs by 51 436 Ontario residents 15 years and older. Incident AGWs peaked in females and
43
44 18 males in the 21-23 year age group, at 3.74 per 1000 and 2.81 per 1000, respectively. HSU for
45
46 19 AGWs peaked in both females and males within the 21-23 age group, at 9.34 per 1000 and 7.22
47
48 20 per 1000, respectively.
49
50

51
52 21 **Conclusions:** To our knowledge, this is the first population-based study of AGW incidence and
53
54 22 HSU in Ontario. The sex and age distribution of individuals with incident and prevalent AGWs
55
56
57
58
59
60

1 in Ontario was similar to that of other provinces before HPV vaccine program implementation
2 in Canada.

3 ARTICLE SUMMARY

- 4 • AGW is considered the first clinical endpoint to evaluate an HPV vaccination program. We
5 report the baseline of AGW epidemiology in Ontario-Canada's most populous and
6 ethnically diverse province- in the years leading up to the introduction of the publicly-
7 funded, female-targeted school-based HPV vaccination program.
- 8 • We used health administrative data to identify incident AGWs and health service
9 utilization (HSU) for AGWs for Ontario residents 15 years and older. These databases are
10 consistent with administrative data used to estimate AGW burden in previous studies.
- 11 • The databases capture only AGW-related health visits to providers working in
12 remuneration models that submit billing data to the province and exclude visits to some
13 sexual health clinics, public health clinics, and community health centres, nor does the
14 data capture undiagnosed and untreated AGWs. Thus, the data are an underestimate of
15 the true incidence of AGWs.
- 16 • The data may be impacted by changes to clinical practices in terms of compensation,
17 coding, treatment etc., which were not accounted for here.

1 Most individuals will acquire human papillomavirus (HPV) at some point in their lifetime. HPV
2 can be transmitted by vaginal, anal, and oral sex, as well as non-penetrative sex including
3 digital-vaginal or skin-to-skin contact (1), and through vertical transmission (2). Although most
4 HPV infections are transient and resolve without treatment, HPV infection can lead to both
5 low risk lesions and cancerous conditions. At least 150 different HPV genotypes have been
6 described, with approximately 40 genotypes having tissue specificity for the anogenital region
7 and oral cavity (3). HPV-6 and -11 accounted for approximately 90% of anogenital warts
8 (AGWs), while HPV-16 and -18 accounted for approximately 70% of cervical cancers prior to
9 vaccine introduction (4). HPV is also associated with other anogenital cancers (vaginal, vulvar,
10 penile, anal canal) and a subset of head and neck squamous cell carcinomas. The licensing of
11 prophylactic HPV vaccines Gardasil® (referred to as HPV4 vaccine, targeting HPV types 6, 11,
12 16, and 18, by Merck & Co., Whitehouse Station, NJ USA), Cervarix® (targeting HPV types 16
13 and 18, by GlaxoSmithKline Biologicals, Rixensart, Belgium), and Gardasil9® (targeting HPV
14 types 6, 11, 16, 18, 31, 33, 45, 52, and 58, by Merck & Co., Whitehouse Station, NJ USA) in
15 countries around the world starting in 2006 introduced the possibility of primary prevention
16 for HPV-related malignancy with both vaccines, and AGWs with HPV4 vaccine.

17 Also known as condylomata acuminata, AGWs appear as multiple, asymmetric epithelial
18 growths on the anogenital skin or mucous membranes. They can fluctuate in size and number,
19 and can be flat, papular, cauliflower-like or keratotic. Anogenital warts are associated with
20 significant costs to the health care system (5) and can cause substantial psychological distress
21 (6, 7), as well as pain and discomfort in some cases in the form of itching, discharge, burning,
22 or bleeding (8, 9). Approximately 70% of HPV-6/11 infections are cleared within 12 months
23 (10, 11), with 10-30% of AGW cases clearing spontaneously within three months (12), and
24 approximately six months median time to clearance of infection (10, 13). Treatments used in
25 Canada include topical therapies applied by a physician or the patient, or physician

1 administered ablative treatments such as cryotherapy, electrosurgery, CO2 laser, or surgical
2 excision (14).

3 Trends in health service utilization (HSU) for AGWs can provide an early indication of the
4 impact of Ontario's HPV vaccine program in preventing HPV infection, by providing valuable
5 information on the burden of AGWs pre- and post-vaccine program implementation. Other
6 countries with HPV vaccination programs have begun reporting significant decreases in the
7 incidence of AGWs in females targeted for vaccination since the introduction of their
8 programs (reviewed by 15, 16). Several Canadian provinces have conducted baseline studies of
9 AGW epidemiology in anticipation of evaluating HPV vaccine program impact, reporting peak
10 incidence rates for males and females ranging from 3.03 to 3.92/1000 population and 3.38 to
11 4.66/1000 population, respectively (5, 17, 18).

12 The objective of our report is to provide a baseline of AGW epidemiology in Ontario in the
13 years leading up to the introduction of the publicly-funded, female-targeted school-based HPV
14 vaccination program, which was introduced in the fall of 2007.

15 **METHODS**

16 **Databases**

17 Neither AGWs nor HPV infection are reportable diseases in Ontario, therefore there are no
18 surveillance data to derive incidence and prevalence. Data are available on AGW-related HSU
19 in Ontario through a variety of health administrative databases. The Ontario Health Insurance
20 Plan (OHIP) database captures fee-for-service claims made by Ontario physicians, and
21 represents claims from approximately 98% of physicians in the province (19). The OHIP
22 database was used to identify physician visits for AGWs using a combination of diagnostic and
23 procedural codes. The Canadian Institute of Health Information (CIHI)-Discharge Abstract

1 Database (DAD) was used to identify hospitalizations for AGWs. The CIHI National Ambulatory
2 Care Reporting System (NACRS) covers hospital and community-based ambulatory care
3 services, and was used to identify emergency department (ED) visits for AGWs. The Same-Day-
4 Surgery (SDS) database was used to identify same day surgeries and procedures for AGWs. The
5 Registered Persons Database (RPDB) contains information on all Ontario residents who are
6 eligible for health care coverage. To be eligible for health care coverage in Ontario residents
7 must be Canadian citizens, landed immigrants, or refugees, with Ontario as their primary or
8 permanent home, and must be present in Ontario for a minimum of 153 days over a 12-month
9 period. Eligible Ontario residents are assigned a unique health card number which permits
10 access to health services available through a publicly funded health care system. The RPDB
11 was used to determine population size, sex, and date of birth in the analysis. These datasets
12 were linked using unique encoded identifiers and analyzed at the Institute for Clinical
13 Evaluative Sciences. These data sources are consistent with administrative data used to
14 estimate AGWs burden in previous studies (5, 17, 18).

15 **Data Sharing Statement**

16 No additional data available.

17 **Population**

18 Ontario is Canada's most populous and ethnically diverse province. We included all Ontario
19 residents 15 years and older with a valid health card number between April 1 2003 and March
20 31 2007, which included fiscal years 2003 to 2006 hereafter referred to as simply year, based
21 on the RPDB.

22 **Case Definition**

23 The outcome of interest was AGW HSU. We identified AGW HSU in the CIHI-DAD, NACRS, and

1 SDS databases using the International Classification of Diseases, 10th revision (ICD-10)
2 diagnostic code for AGWs, which is A630. There was no pre-existing validated algorithm for
3 identifying AGW cases in the OHIP database; therefore, we identified codes with potential
4 relevance to AGWs through the Ministry of Health and Long Term Care (MOHLTC) Chapter 4
5 Claims Submissions (2003 and 2014 editions), the Ontario Medical Association Section on
6 General & Family Practice (SGFP) Common Family Practice Codes (2011), the MOHLTC OHIP
7 Schedule of Benefits for Physician Services (2013), and the Practice Solutions (PSS) electronic
8 medical record system as an example of a common electronic medical record and billing
9 system used in family practice (supplementary figure 1). We reviewed the list of diagnostic
10 and procedural codes in consultation with physicians having experience in sexual and
11 reproductive health services and combined in algorithms for AGW case definitions. Smith et al
12 report using similar OHIP diagnostic and procedural codes in a recent analysis of AGWs in
13 Ontario (20). We conducted sensitivity analyses to identify the most probable case definition
14 for AGWs. The final algorithm to identify AGW HSU in OHIP was as follows: 099 only if billed
15 with Z117; or, 079 only if billed with Z117; or, 629 only if billed with Z117; or, Z549 or Z758;
16 or, Z733, Z736, or Z769 only in females; or, Z767 or Z701 only in males. Any of these ten code
17 combinations comprised of a diagnostic and/or procedural code constituted a HSU for a case
18 of AGWs.

19 We conducted descriptive analysis of AGW-related HSU by age group, sex, and fiscal year. Age
20 groups were designed to provide sufficient granularity in the ages surrounding peak AGW HSU
21 and incident AGWs, and to provide baseline data on age groups targeted in the provincial HPV
22 vaccination program as they age. Three-year age groups were used for 15 to 44 year olds, 10-
23 year age groups were used for 45 to 84 year olds, and a separate age group was used for
24 individuals 85 years and older, to be in line with the epidemiology of AGWs. Reported rates
25 are either rates of total HSU for AGWs i.e. every AGW-related health care visit; or, as rates of

1 incident AGWs i.e. AGW cases preceded by 12-months without an AGW visit divided by the
2 number of health card holders. This is similar to definitions used for incident cases in previous
3 studies (5, 17, 18, 21). The first year of the study functioned to exclude prevalent cases when
4 estimating the rate of incident AGWs, thus, AGWs incidence data are available for 2004 to
5 2006, whereas total HSU data are available for 2003 to 2006. Rates reported for multiple years
6 are the average annual rates. Trends in AGWs were analyzed separately for OHIP, NACRS,
7 DAD, and SDS, as these databases represent different health care settings. Rates are provided
8 per 1000 population.

9 **Sensitivity Analysis**

10 One procedural code used in our AGW algorithm was for in-office chemical and/or
11 cryotherapy, Z117, in conjunction with a diagnostic code. Anogenital warts, however, can be
12 treated using other therapies including patient-administered topical agents. Secular changes
13 in the treatment of AGWs towards more patient-applied therapies could skew AGW rates
14 because there are no corresponding codes to capture such treatment in administrative
15 databases. To examine the potential impact of this, we analyzed age and sex specific trends
16 in Z117 and compared these results to AGW trends using the full AGW case algorithm, and
17 then with the OHIP code combinations that included Z117.

18 This study was approved by the Institutional Review Boards at Sunnybrook Health Sciences
19 Centre and Public Health Ontario in Toronto, Canada. The Public Health Ontario ERB approval
20 number is 2014-056.01.

21 **RESULTS**

22 Combining physician office visits, SDS, hospitalizations, and ED visits for Ontario residents 15
23 years and older between fiscal years 2003 and 2006, 51 436 individuals had 123 247 health

1 service visits for AGWs (Figure 1). Consistent with expected health care patterns for AGWs,
2 average annual HSU for AGWs varied across the databases (hospitalizations: 0.01 per 1000;
3 SDS: 0.23 per 1000; ED: 0.04 per 1000; and physician office visits: 2.74 per 1000), as did the
4 average annual rate of incident AGWs (hospitalizations: 0.01 per 1000; SDS: 0.18 per 1000; ED:
5 0.03 per 1000; physician office visits: 1.19 per 1000). As revealed by comparing the number of
6 unique individuals overall in all four databases (51 436) with the sum of the number of unique
7 individuals in each separate database (63 932), some individuals utilized more than one type
8 of health service for AGW diagnosis and/or treatment. From 2004 to 2006, the total number of
9 physician office visits for AGWs was just over double the estimated number of new cases over
10 the same period of time (data not shown). Same day surgery accounted for 7.6% of the visits,
11 ED accounted for 1.3% of the visits, hospitalizations accounted for 0.4% of the visits, while
12 physician office visits accounted for 90.7% of visits (Figure 1). As physician visits captured in
13 the OHIP database accounted for the vast majority of visits and had the highest number of
14 unique individuals, the analysis will focus primarily on the OHIP database.

15 **AGW incidence**

16 The rate of incident AGWs during the study period varied with age and sex. Females in the 15-
17 38 age group were more frequently diagnosed with AGWs in hospitals and SDS than males in
18 the same age group (Figure 2 a, b). AGW incidence rates were more similar between sexes for
19 AGWs diagnosed in ED, however AGW incidence was higher in females < 21 years and males
20 21-26 years compared to the opposite sex of the same age groups (Figure 2 c). The rate of
21 incident AGWs in physician offices also varied with age and sex. Anogenital warts incidence
22 peaked within the 21-23 age group for both females and males at rates of 3.74 per 1000 and
23 2.81 per 1000, respectively (Figure 3). In the 15 to 26 age groups, incidence was higher
24 amongst females compared to males, but between the ages of 27 to 41 years, the reverse was
25 true, followed by similar rates between the sexes among those 42 years of age and older.

1 Trends by age group and sex

2 For females in the 15-17 age group, the rate of incident AGWs decreased from 1.21 in 2004, to
3 1.01 in 2005, and 0.95 in 2006 (Figure 4). In contrast, the rate of incident AGWs increased in
4 females in the 24-26 age group from 2.77 in 2004, to 2.94 in 2005, to 3.02 in 2006. The rate of
5 incident AGWs showed little fluctuation in males from 2004 to 2006, with the exception of
6 males in the 21-23 age group, which changed from 2.77 in 2004, to 3.01 in 2005, to 2.66 in
7 2006. From 2004 to 2006, females represented a larger proportion of the new AGW cases in
8 Ontario, but comprised a similar proportion of the total AGW-related HSU relative to males
9 (data not shown).

10 From 2003 to 2006, the total HSU for AGWs captured by the physician office visits peaked in
11 both females and males in the 21-23 age group, at a rate of 9.34 per 1000 and 7.22 per 1000,
12 respectively (Figure 5). Health service utilization for AGWs was higher amongst females in the
13 15 to 26 age groups compared to males, but between the 27 to 74 age bands, the reverse was
14 true.

15 Sensitivity Analysis

16 To investigate whether secular changes in the treatment of AGWs towards more patient-
17 applied therapies could be skewing AGW rates we analyzed age and sex specific trends in Z117
18 over the study period and compared these results to AGW trends using the full AGW case
19 algorithm, and then with the OHIP code combinations that included Z117 for case
20 identification. The results of the sensitivity analysis among 21-23 year old females is provided
21 as this was the age of peak AGW incidence for females (supplementary figure 2a, 2b, 2c). The
22 results revealed that Z117 age distribution and rates for 15-38 year olds exhibited different
23 rates and trends than those observed in our AGW cases, thus our observed AGW trends were
24 unlikely a reflection of trends in Z117 treatment or coding practices.

1 DISCUSSION

2 This is the first population-based study of HSU for AGWs in Ontario, and was conducted using
3 individual-level health administrative data from April 1 2003 to March 31 2007. Similar to
4 previous studies from other regions, incident AGWs peaked in females in the 21-23 age group
5 (5, 17, 18). Although several previous studies reported peak incidence in males occurring at an
6 older age than females (5, 18, 22), we found a similar age of peak incidence in males and
7 females, which has been reported, but less frequently (17). However, incidence in males
8 remained stable from the 21-23 and 24-26 age groups (2.81/1000 and 2.79/1000,
9 respectively), thus peak incidence spanned the 21-26 age group in males (Figure 3).

10 The two-fold higher total number of health service visits compared with incident AGW visits
11 for cases from 2004 to 2006 likely reflects multiple treatments for a single episode or
12 recurrence of AGWs within the 12-month window. This difference may also reflect the
13 continued treatment of prevalent cases from the start of the study period, which could
14 contribute to total visits but not total new cases as the 12-month washout removed prevalent
15 cases from the estimation of new cases.

16 The decreasing incidence of AGWs in females in the 15-17 year age band is important to
17 consider as this is the age group where potential HPV vaccine program impact will be first
18 observed and may complicate future assessment of HPV vaccine program impact.

19 Changes to cervical cancer screening policy may account for the decrease in AGWs in the 15-
20 17 year age band because some cases of AGWs may be picked up incidentally during a cervical
21 screening. The Ontario Cervical Screening Program (OCSP) was launched in June 2000 and
22 recommended Pap smears for any female who had been sexually active, with screening at
23 one-year intervals, and after three normal Pap smears, screening was recommended every
24 two years. The recommendations changed in 2005 to screening starting within three years of

1 first sexual activity, with screening recommended every two to three years after three
2 consecutive normal Pap smears. Thus, from 2005, Pap smears would have been conducted less
3 frequently and age of first Pap may have been later. These changes could impact the rate of
4 AGW diagnosis in females if the Pap smear procedure was a significant means of identifying
5 AGWs; unfortunately investigation of how changes to Pap smear policy relate to AGWs
6 diagnosis and treatment rates was beyond the scope of this study.

7 The observation that females are more frequently diagnosed with AGWs in hospitals and SDS
8 settings than males likely reflects gynecological and pregnancy-related services rendered in
9 these settings, which presents the opportunity for AGW diagnosis. This is supported by the
10 observation that the frequency of AGW visits in these sites is much higher for females of
11 reproductive age (late teens to late 30's) compared to males of the same age, whereas there
12 is little difference between the sexes beyond 39 years of age. The same argument can be
13 made for physician office visits, where females also seek reproductive health services. The
14 higher rate of AGW diagnosis in ED in the male 21-26 age group compared to females of the
15 same age is interesting and may reflect sex differences in health-seeking behaviour in Ontario
16 more generally and requires further study.

17 Relying on health administrative data does not capture undiagnosed and untreated AGWs,
18 thereby underestimating the true incidence of AGWs; although this would also be a limitation
19 if surveillance data were available. The OHIP database captures only AGW-related health visits
20 to providers working in remuneration models that submit billing data and excludes visits to
21 some sexual health clinics, public health clinics, and community health centres. The literature
22 indicates that STI clinics report higher rates of AGWs than general practices and that certain
23 populations are more likely to utilize these types of services (23, 24), including individuals
24 without valid health card numbers. Thus, the findings reported here are likely an
25 underestimate of incidence and HSU for AGWs in Ontario. As described in the sensitivity

1
2
3 1 analysis, we were unable to identify AGWs treated topically by the patient, thus, such cases
4
5 2 may be missing from the counts. Although the study period spans a relatively short window of
6
7 3 four years, the data may be impacted by changes to clinical practices in terms of
8
9 4 compensation, coding, treatment etc., which have not been accounted for here. Conversely,
10
11 5 this study is not limited by self-reporting.
12
13

14
15 6 Unlike cervical cancer, which develops over years, AGWs are an early indicator of HPV
16
17 7 transmission. The objective of our report was to provide a baseline of AGW epidemiology in
18
19 8 Ontario in the years leading up to the introduction of the publicly-funded, female-targeted
20
21 9 school-based HPV vaccination program. Subsequent studies of AGW epidemiology in Ontario
22
23 10 will build on this knowledge to assess the impact of the vaccination program.
24
25

26 27 **Acknowledgements:**

28
29 12 This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is
30
31 13 funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC).
32
33 14 The opinions, results and conclusions reported in this paper are those of the authors and are
34
35 15 independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is
36
37 16 intended or should be inferred. Parts of this material are based on data and information
38
39 17 compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements
40
41 18 expressed herein are those of the author, and not necessarily those of CIHI.
42
43
44
45

46 47 **Competing interests:**

48
49 21 None.
50
51

52 53 **Funding:**

54
55 23 Funding was provided by Public Health Ontario.
56
57
58
59
60

1
2
3 1 **Ethics:**
4

5
6 2 This study was approved by the Research Ethics Board at Sunnybrook Health Sciences Centre
7
8 3 and the Ethics Review Board at Public Health Ontario, ERB approval 2014-056.01.
9

10
11 4 **Contributorship Statement:**
12

13
14 5 SLD conceived of the study, participated in study design, data interpretation, and writing of
15
16 6 the manuscript. FMG participated in study design, data analysis and interpretation, supervised
17
18 7 the statistical analysis, and wrote the first draft of the manuscript and revised drafts. CC had
19
20 8 full access to the data and performed data analysis. SEW provided clinical expertise, and
21
22 9 participated in study design, data interpretation, and writing of the manuscript. SD provided
23
24 10 clinical expertise and participated in data interpretation and writing of the manuscript. LCR
25
26 11 participated in study design, data analysis and interpretation, and writing of the manuscript.
27
28
29

30
31 12 **Key Messages Box**
32

- 33
34 13 • Anogenital warts are an early indicator of HPV transmission in a population relative to
35
36 14 cervical cancers, which take more time to develop.
37
38 15 • Anogenital warts incidence and health service utilization in Ontario peaked in the 21-
39
40 16 23 age group for both females and males.
41
42 17 • In the three years leading up to the Ontario HPV4 program, the sex and age
43
44 18 distribution of AGWs was found to be similar to other Canadian provinces before
45
46 19 widespread program implementation.
47
48
49

50
51 21 **References**
52

- 53
54 22 1. Winer, RL, Lee, SK, Hughes, JP, et al. Genital human papillomavirus infection:
55
56 23 incidence and risk factors in a cohort of female university students. *Am J Epidemiol*
57
58 24 2003;157(3),218-226.
59
60

- 1
2
3 1 2. Freitas AC, Mariz FC, Silva MA, et al. Human papillomavirus vertical transmission: review of
4
5 2 current data. *Clin Infect Dis* 2013;May;56(10):1451-6.
- 6
7
8 3 3. Nyitray AG, Iannacone MR. The epidemiology of human papillomaviruses. *Curr Probl*
9
10 4 *Dermatol* 2014;45:75-91.
- 11
12 5 4. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall
13
14 6 we vaccinate and screen? The international perspective. *Int J Cancer* 2004; Aug 20;111(2):278-
15
16 7 85.
- 17
18 8 5. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in
19
20 9 Canada. *Sex Transm Infect* 2009;Apr;85(2):111-5.
- 21
22
23 10 6. Wang KL, Jeng CJ, Yang YC, et al. The psychological impact of illness among women
24
25 11 experiencing human papillomavirus-related illness or screening interventions. *J Psychosom*
26
27 12 *Obstet Gynaecol* 2010; Mar;31(1):16-23.
- 28
29 13 7. Drolet, M. et al. The impact of anogenital warts on health-related quality of life: a 6-month
30
31 14 prospective study. *Sexually transmitted diseases*, 2011, 38(10) :949-956.
- 32
33 15 8. Lynde C, Vender R, Bourcier M, et al. Clinical features of external genital warts. *J Cutan*
34
35 16 *Med Surg* 2013; Dec;17Suppl2:S55-60.
- 36
37
38 17 9. Richards S. An overview of genital warts. *Nurs Stand* 2014; Feb 12-18;28(24):46-50.
- 39
40 18 10. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of
41
42 19 human papillomavirus infections in a cohort of 290 US men. *J Infect Dis*
43
44 20 2008;Sep15;198(6):827-35.
- 45
46 21 11. Insinga RP, Dasbach EJ, Elbasha EH, et al. Incidence and duration of cervical human
47
48 22 papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple
49
50 23 analytic perspectives. *Cancer Epidemiol Biomarkers Prev* 2007;Apr;16(4):709-15.
- 51
52 24 12. Stone KM. Human papillomavirus infection and genital warts: update on epidemiology and
53
54 25 treatment. *Clin Infect Dis* 1995;Apr;20 Suppl1:S91-7.
- 55
56 26 13. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, Koutsky LA. Development
57
58 27 and duration of human papillomavirus lesions, after initial infection. *Journal of Infectious*
59
60 28 *Diseases*. 2005 Mar 1;191(5):731-8.

- 1
2
3 1 14. The Canadian Guidelines on Sexually Transmitted Infections Treatment. [http://www.phac-](http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php)
4 [aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php](http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php) Accessed July 2015.
5
6
7 3 15. Hariri S, Markowitz LE, Dunne EF, et al. Population impact of HPV vaccines: summary of
8 early evidence. *J Adolesc Health* 2013;Dec;53(6):679-82.
9
10 5 16. Garland SM. The Australian experience with the human papillomavirus vaccine. *Clin Ther*
11 2014;Jan1;36(1):17-23.
12
13 6
14 7 17. Kliewer EV, Demers AA, Elliott L, et al. Twenty-year trends in the incidence and
15 prevalence of diagnosed anogenital warts in Canada. *Sex Transm Dis* 2009; Jun;36(6):380-
16 6.
17
18 9
19 10 18. Steben M, Ouhoumane N, Rodier C, et al. Temporal trends in genital warts among
20 individuals covered by the public prescription drug insurance plan in the province of
21 Quebec, Canada, from 1998 to 2007. *J Low Genit Tract Dis* 2013;Apr;17(2):147-53.
22
23 12
24 13 19. Chan, BT & Schultz, SE. Supply and utilization of general practitioner and family physician
25 services in Ontario. Institute for Clinical Evaluative Sciences. Toronto, ON: Institute for
26 Clinical Evaluative Sciences 2005. [http://www.ices.on.ca/Publications/Atlases-and-](http://www.ices.on.ca/Publications/Atlases-and-Reports/2005/Supply-and-utilization)
27 [Reports/2005/Supply-and-utilization](http://www.ices.on.ca/Publications/Atlases-and-Reports/2005/Supply-and-utilization) . Accessed July 2015.
28
29 16
30 17 20. Smith LM, Strumpf EC, Kaufman JS, et al. The early benefits of human papillomavirus
31 vaccination on cervical dysplasia and anogenital warts. *Pediatrics* 2015; May;135(5):e1131-
32 40.
33
34 19
35 20 21. Camenga, DR, Dunne, EF, Desai, MM, et al. Incidence of Genital Warts in Adolescents and
36 Young Adults in an Integrated Health Care Delivery System in the United States Before
37 Human Papillomavirus Vaccine Recommendations. *Sexually Transm Dis*,2013;40(7),534-
38 538.
39
40 23
41 24 22. Mikolajczyk RT, Kraut AA, Horn J, et al. Changes in incidence of anogenital warts
42 diagnoses after the introduction of human papillomavirus vaccination in Germany-an
43 ecologic study. *Sex Transm Dis* 2013;Jan;40(1):28-31.
44
45 26
46 27 23. Xi, LF & Koutsky, LA. Epidemiology of genital human papillomavirus infections. *Bulletin de*
47 *l'Institut Pasteur*, 1997;95(3),161-178.
48
49 28
50 29 24. Brackbill, RM, Sternberg, MR, & Fishbein, M. Where do people go for treatment of sexually
51 transmitted diseases? *Family Planning Perspectives*, 1999;10-15.
52
53 30
54
55 31

56
57 **Licence for Publication**
58
59
60

1 The Corresponding Author has the right to grant on behalf of all authors and does grant on
2 behalf of all authors, an exclusive license (or non-exclusive for government employees) on a
3 worldwide basis to the BMJ and co-owners or contracting owning societies (where published by
4 the BMJ on their behalf), and its Licensees to permit this article (if accepted) to be published
5 in Sexually Transmitted Infections and any other BMJ products and to exploit all subsidiary
6 rights, as set out in our license.

7

8 **FIGURE LEGENDS**

9 Figure 1. Counts and rates of AGWs by data source for Ontario residents 15 years and older,
10 with a valid health card number, fiscal years 2003 to 2006. Rates are average annual for
11 indicated period of time.

12 ¹ 2003 to 2006

13 ² 2004-2006, with 2003 as a washout to exclude prevalent cases

14 Health service utilization, HSU

15 Figure 2. Average annual rate of incident AGWs captured by hospitalizations (DAD)(a); same
16 day surgery (b); and emergency department visits (NACRS)(c), by sex and age group, fiscal
17 years 2004 to 2006.

18 Figure 3. Average annual rate of incident AGWs captured by physician office visits, by sex and
19 age group, fiscal years 2004 to 2006.

20 Figure 4. Annual incident AGWs captured by physician office visits, by fiscal year, sex, and age
21 group, fiscal years 2004 to 2006.

- 1
2
3 1 Figure 5. Average annual health service utilization (HSU) for AGWs captured by physician
4 office visits, by sex and age group, fiscal years 2003 to 2006.
5
6 2
7
8 3 Supplementary figure 1. Table of AGW-related diagnostic and procedural codes used by
9 physician offices.
10
11 4
12
13 5 Supplementary figure 2a. Sensitivity analysis of billing code for physician-administered, in-
14 office chemical or cryotherapy, Z117. Age distribution of HSU with code Z117 for fiscal year
15 6
16 2004.
17 7
18
19 8 Supplementary figure 2b. Age-specific trends in code Z117 in females.
20
21 9
22 23
24 9 Supplementary figure 2c. Age-specific trends in billing code combinations that include Z117,
25 10
26 for 21-23 year old females.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Counts and rates of AGWs by data source for Ontario residents 15 years and older, with a valid health card number, fiscal years 2003 to 2006. Rates are average annual for indicated period of time.

1 2003 to 2006

2 2004-2006, with 2003 as a washout to exclude prevalent cases

Health service utilization, HSU

215x120mm (300 x 300 DPI)




Figure 2. Average annual rate of incident AGWs captured by hospitalizations (DAD)(a); same day surgery (b); and emergency department visits (NACRS)(c), by sex and age group, fiscal years 2004 to 2006. 173x130mm (300 x 300 DPI)




Figure 3. Average annual rate of incident AGWs captured by physician office visits, by sex and age group, fiscal years 2004 to 2006.
142x102mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Annual incident AGWs captured by physician office visits, by fiscal year, sex, and age group, fiscal years 2004 to 2006.
173x109mm (300 x 300 DPI)

Review only





Figure 5. Average annual health service utilization (HSU) for AGWs captured by physician office visits, by sex and age group, fiscal years 2003 to 2006.
148x103mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Code	Description
ICD-10	
A630	
OHIP	
Diagnostic Codes	
099	venereal disease, TD, condyloma, Duchennes, herpes genitalis, chlamydia,
079	condyloma accuminata, rabies, viral disease, other viral disease, viral illness
629	Warts, venereal, other disorders, Other diseases or disorders not specified elsewhere-genital organs female, other disorders of female genital organs, condylomata, leukorrhea
078	verruca(plantar wart), warts, all types, other viral disease, warts
K028	STD, BBD mgmt
Procedural Codes	
Z117	Chemical Rx wart (plantar, genital)
Z549	Digestive system surgical procedures: Rectum: Destruction: Fulguration of condylomata (local anaesthesia)
Z701	Male genital surgical procedures: Excision: condylomata (local anaesthesia)
Z733	Female genital surgical procedures: Excision: condylomata (chem or cryo surgery)
Z736	Female genital surgical procedures: Excision: condylomata (local anaesthesia, surgical excision OR electrodesiccation OR CO2 laser)
Z758	Digestive system surgical procedures: Rectum: Destruction: Fulguration of condylomata (general anaesthesia)
Z767	Male genital surgical procedures: Excision: condylomata (general anaesthesia)
Z769	Female genital surgical procedures: Excision: condylomata (general anaesthesia, surgical excision OR electrodesiccation OR CO2 laser)

Supplementary figure 1. Table of AGW-related diagnostic and procedural codes used by physician offices.
173x163mm (300 x 300 DPI)



Supplementary figure 2. Sensitivity analysis of billing code for physician-administered, in-office chemical or cryotherapy, Z117. Age distribution of HSU with code Z117 for fiscal year 2004 (a); age-specific trends in code Z117 in females (b); age-specific trends in billing code combinations that include Z117, for 21-23 year old females (c).

173x104mm (300 x 300 DPI)

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a	Identify the report as a protocol of a systematic review See Page 1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number N/A
Authors:		
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author See Page 1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review See Page 14
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments N/A
Support:		
Sources	5a	Indicate sources of financial or other support for the review See Page 14
Sponsor	5b	Provide name for the review funder and/or sponsor See Page 14
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol See Page 14
INTRODUCTION		
Rationale	6	Describe the rationale for the review in the context of what is already known See Pages 4 & 5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) See Page 5
METHODS		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review N/A
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage See Pages 5-8
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated N/A
Study records:		
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review See Pages 5 & 6

Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	N/A
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms done independently, in duplicate), any processes for obtaining and confirming data from investigators	N/A
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	See Pages 5-8
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	N/A
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	N/A
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	N/A
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	See Page 8
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	N/A
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	N/A
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	N/A

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.